Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: March 31, 2024

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _____________

Commission File Number: 001-38190

Panacea Life Sciences Holdings, Inc.

(Exact name of registrant as specified in its charter)

Nevada		27-1085858
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

5910 S University Blvd, C18-193, Greenwood Village, CO 80121

(Address of principal executive offices, Zip Code)

800-985-0515

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

	Large Accelerated Filer ☐	Accelerated Filer ☐
	Non-Accelerated Filer ☒	Smaller reporting company ☒
		Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 17,645,352 shares of common stock, par value $0.0001 per share, outstanding as May 1, 2024.

TABLE OF CONTENTS

		Page

	PART I – FINANCIAL INFORMATION
Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	24
Item 4.	Controls and Procedures	24

	PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	24
Item 1A.	Risk Factors	24
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3.	Defaults Upon Senior Securities	24
Item 4.	Mine Safety Disclosures	25
Item 5.	Other Information	25
Item 6.	Exhibits	25
	Signatures	27

PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements.

Panacea Life Sciences Holdings, Inc. and Subsidiary

Unaudited Condensed Consolidated Balance Sheets

	March 31, 2024			December 31, 2023
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	107,643		$	100,922
Accounts receivable, net		270,851			263,970
Other receivables, related party		-			-
Inventory		4,062,827			4,013,525
Marketable securities related party		9,504			14,933
Prepaid expenses and other current assets		192,133			263,003
TOTAL CURRENT ASSETS		4,642,958			4,656,353

Operating lease right-of-use asset, net, related party		3,685,567			3,864,591
Property and equipment, net		6,069,570			6,448,068
Intangible assets, net		-			-
Goodwill		3,014,450			3,014,450
TOTAL ASSETS	$	17,412,545		$	17,983,462

LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	5,178,214		$	4,629,591
Operating lease liability, current portion, related party		3,055,134			2,913,781
Note payable-current, related party		11,772,259			11,397,617
First Bank note payable		287,111			292,942
Convertible note payable, net		-			115,000
Paycheck protection loan, SBA Loan		99,100			99,100
TOTAL CURRENT LIABILITIES:		20,391,818			19,448,031

Operating lease liability, long-term portion, related party		3,070,391			3,254,021
Other long-term liabilities, related party		3,572,864			3,572,864
TOTAL LIABILITIES		27,035,073			26,274,916

Commitments and contingencies		-			-

STOCKHOLDERS’ EQUITY
Series A Preferred Stock: $0.0001 Par Value, 1,000 shares designated; 0 and 350 shares issued and outstanding on March 31, 2024 and December 31, 2023 respectively.		-			-
Series B-1 Preferred: $0.0001 Par Value, 32,000,000 shares designated; 1,500,000 and 1,500,000 shares issued and outstanding on March 31, 2024 and December 31, 2023 respectively.		150			150
Series B-2 Preferred: $0.0001 Par Value, 6,000,000 shares designated; 6,000,000 and 6,000,000 shares issued and outstanding on March 31, 2024 and December 31, 2023 respectively.		600			600
Series C Preferred: $0.0001 Par Value, 1,000,000 shares designated; 1,000,000 and 1,000,000 shares issued and outstanding on March 31, 2024 and December 31, 2023 respectively.		100			100
Series C-1 Preferred: $0.0001 Par Value, 10,000 shares designated and 10,000 and 10,000 shares issued and outstanding on March 31, 2024 and December 31, 2023 respectively.		1			1
Series C-2 Preferred: $0.0001 Par Value, 100 and 0 shares designated and 100 and 0 shares issued and outstanding on March 31, 2024 and December 31, 2023 respectively.		-			-
Series D Preferred: $0.0001 Par Value, 10,000 shares designated and 10,000 and 10,000 shares issued and outstanding on March 31, 2024 and December 31, 2023 respectively.		1			1
Series E Preferred: $0.0001 Par Value, 3,853,000 shares designated and 3,853,000 and 3,853,000 shares issued and outstanding on March 31, 2024 and December 31, 2023 respectively.		385			385
Common Stock: $0.0001 Par Value, 650,000,000 shares authorized; 18,311,352 and 17,645,352 shares issued and outstanding on March 31, 2024 and December 31, 2023 respectively.		1,832			1,765
Additional paid in capital		25,743,375			25,628,442
Accumulated deficit		(35,368,972	)		(33,922,898	)
TOTAL STOCKHOLDERS’ EQUITY		(9,622,528	)		(8,291,454	)

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	17,412,545		$	17,983,462

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Panacea Life Sciences Holdings, Inc. and Subsidiary

Unaudited Condensed Consolidated Statements of Operations

	2024			2023
	Three months ended March 31
	2024			2023
REVENUE	$	1,056,447		$	677,481
COST OF SALES		390,282			451,872
GROSS PROFIT		666,165			225,609

OPERATING EXPENSES
Production related operating expenses		1,474,475			1,258,159
General and administrative expenses		249,038			257,413
TOTAL OPERATING EXPENSES		1,723,513			1,515,572

LOSS FROM OPERATIONS		(1,057,348	)		(1,289,963	)

OTHER INCOME (EXPENSES)
Interest expense		(429,672	)		(380,157	)
Unrealized gain (loss) on marketable securities, net		5,053			(182,255	)
Realized gain (loss) on sale of securities		(376	)		-
Other income (loss)		-			-
Employer retention credit		-			-
Rental Income		36,269			60,332
Gain on extinguishment of debt		-			748
TOTAL OTHER INCOME (EXPENSE)		(388,726	)		(501,332	)

INCOME (LOSS) BEFORE INCOME TAXES		(1,446,074	)		(1,791,295	)

TAXES		-			-

NET INCOME (LOSS)	$	(1,446,074	)	$	(1,791,295	)

Per-share data
Basic and diluted loss per share	$	(0.09	)	$	(0.12	)

Weighted average number of common shares outstanding		16,492,589			14,965,317

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

PANACEA LIFE SCIENCES HOLDINGS, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY

(unaudited)

	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
	Preferred Stock				Common Stock				Additional Paid-in		Accumulated			Total Stockholder’s
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance as of December 31, 2023		12,838,350	$	1,238		17,645,352	$	1,765	$	25,628,442	$	(33,922,898	)	$	(8,291,454	)
Shares issued in respect of the merger						-		-		-					-
Shares issued in settlement of convertible note		-		-		666,000		67		114,933					115,000
		-		-		-		-		-
Net Loss		-		-		-		-		-		-			(1,446,074	)
Balance as of March 31, 2024		12,838,350	$	1,238		18,311,352	$	1,832	$	25,743,375	$	(33,922,898	)	$	(9,622,528	)

Balance as of December 31, 2022		8,530,000	$	853		14,965,317	$	1,497	$	23,760,704	$	(25,907,597	)	$	(2,144,544	)
Balance		8,530,000	$	853		14,965,317	$	1,497	$	23,760,704	$	(25,907,597	)	$	(2,144,544	)
Shares issued in respect of the merger		-		-		-		-		-		-			-
Issuance of common shares for services						-		-		-					-
Shares issued in settlement of convertible note		-		-		540,000		54		134,946					135,000
Net Loss		-		-		-		-		-		(1,791,295	)		(1,791,295	)
Balance as of March 31, 2023		8,530,000	$	853		15,505,317	$	1,551	$	23,895,650	$	(27,698,892	)	$	(3,800,839	)
Balance		8,530,000	$	853		15,505,317	$	1,551	$	23,895,650	$	(27,698,892	)	$	(3,800,839	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Panacea Life Sciences, Inc.

Statements of Cash Flows

	2024			2023
	For the months ended March 31,
	2024			2023
Cash flows from operating activities
Net income (loss)	$	(1,446,074	)	$	(1,791,295	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation		383,498			422,554
Realized gain on sale of securities		376			-
Unrealized (gain)/loss on marketable securities		5,053			182,255
Amortization of debt discount and non-cash interest expense		-			38,329
Changes in operating assets and liabilities
Accounts receivable		(6,881	)		(68,660	)
Inventory		(49,302	)		353,662
Prepaid expense and other assets		70,870			34,552
Accounts payable and accrued expenses		548,623			400,059
Operating lease liability, net		136,747			114,693
Net cash used in operating activities		(357,090	)		(313,851	)

Cash flows from investing activities
Net fixed asset acquisitions		(5,000	)		(15,220	)
Net Cash provided by (used in) investing activities		(5,000	)		(15,220	)

Cash flows from financing activities
Repayment of notes payable		(5,831	)		(135,000	)
Payments of principal on notes payable – related party		(74,000	)		(65,000	)
Proceeds from Notes payable - related party		448,642			595,352
Cash provided by financing activities		368,811			395,352

Net increase (decrease) in Cash and Cash Equivalents		6,721			66,281
Cash and Cash Equivalents, Beginning of Period		100,922			6,951
Cash and Cash Equivalents, End of Period	$	107,643		$	73,232

Supplemental Disclosure of Cash Flow Information
Cash paid for income taxes during the year	$	-		$	-
Interest payments during the year	$	-		$	-

Noncash investing and financing activity
Conversion of note payable to common stock	$	(115,000	)	$	-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

PANACEA LIFE SCIENCES HOLDINGS, INC. AND SUBSIDIARY

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2024

NOTE 1 - NATURE OF ORGANIZATION

Organization and Business Description

Panacea Life Sciences Holdings, Inc. (OTCQB: PLSH) is a holding company organized as a plant-based natural health ingredient and product company, specializing in the development, manufacturing, research, and distribution of products within the $134B and rapidly growing natural health and wellness market segment for both humans and animals.

Established in 2017, the company’s first subsidiary, Panacea Life Sciences, Inc. (PLS), is dedicated to the production, distribution, research, and manufacturing of premium-quality nutraceuticals, cannabinoids, mushrooms, kratom, and other natural, plant-based ingredients and products. Operating from a cutting-edge 51,000 square foot cGMP facility located in Golden, Colorado, PLS is committed to delivering high-quality solutions in the field of natural health and well-being. Panacea also offers the purest natural remedies within its branded product lines for every aspect of life: PANA Health™, PANA Beauty®, PANA Sport™, PANA Pet®, PANA Pure® and PANA Life™. If you would like more information, please visit www.panacealife.com.

Panacea Distro, the second subsidiary of Panacea Life Sciences Holdings, Inc., manages six retail locations and a distribution center situated in the Tampa, Florida area. These establishments provide a diverse range of products, including Nitro Kava, Kratom, Hemp, VAPE products, and various beverages, with a primary focus on promoting alternative health and wellness. The Panacea Distro business is segmented into two distinct areas—the retail stores and the cash & carry distribution warehouse. The retail stores are poised to evolve into franchise stores, with the intention of eventually adopting the name “PANA KAVA JAVA.” This strategic move is part of our plan to establish a franchise model based on the success of these existing retail locations.

In the coming months, a third business entity, Pana Kava Java (PKJ), is set to emerge as the franchisor company, with a scheduled launch in Q3-Q4 2024. Pana Kava Java is committed to establishing a unique franchise model, drawing inspiration from the European-style café concept. Patrons will have the opportunity to savor infused coffees and beverages, indulge in vaping, and enjoy an array of infused baked goods in a welcoming atmosphere. Pana Kava Java, as the franchisor, will offer franchise rights to individuals interested in opening stores/cafés, enabling them to sell products or services under the PKJ brand, leveraging our expertise and intellectual property. Currently, active efforts are underway in developing the franchisor plan, encompassing aspects such as business development, flagship store establishment, legal document preparation, marketing and packaging strategies, as well as the recruitment and training of franchisees.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation and principles of consolidation

The Company’s consolidated financial statements include the financial statements of Panacea Life Sciences, Inc.

The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America and the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) for interim financial information, which includes consolidated unaudited interim financial statements and present the consolidated unaudited interim financial statements of the Company and its wholly-owned subsidiaries as of March 31, 2024. Accordingly, they do not include all of the information and notes required by accounting principles generally accepted in the United States of America. All intercompany transactions and balances have been eliminated. In the opinion of management, all adjustments necessary to present fairly our financial position, results of operations, stockholders’ equity and cash flows as of March 31, 2024, and 2023, and for the periods then ended, have been made. Those adjustments consist of normal and recurring adjustments. Operating results for the three ended March 31, 2024 and 2023 are not necessarily indicative of the results that may be expected for any subsequent quarters or for the year ending December 31, 2024. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted.

Going concern

These unaudited condensed consolidated financial statements are presented on the basis that the Company will continue as a going concern. Panacea has combined with Panacea Life Sciences Holdings, Inc. so the below items reflect the consolidated company. The going concern concept contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since our inception in later 2017, we have generated losses from operations. As of March 31, 2024, our accumulated deficit was $35.369 million, and we had $0.117 million in cash and liquid stock. These factors raise doubt about the Company’s ability to continue as a going concern for a period of 12 months from the issuance date of this report. Management cannot provide assurance that the Company will ultimately achieve or maintain profitable operations or become cash flow positive or raise additional debt and/or equity capital. In addition, due to insufficient revenue, we will need to obtain further funding through public or private equity offerings, debt financing, collaboration arrangements or other sources in order to maintain active business operations. We currently do not have sufficient cash flow to pay our ongoing financial obligations on a consistent basis. The issuance of any additional shares of Common Stock, preferred stock or convertible securities could be substantially dilutive to our shareholders. In addition, adequate additional funding may not be available to us on acceptable terms, or at all. These unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Use of Estimates

The Unaudited Condensed Consolidated Financial Statements have been prepared in conformity with US GAAP and required management of the Company to make estimates and assumptions in preparation of these statements. Actual results may differ significantly from those estimates. Significant estimates made by management include but are not limited to the useful life of property and equipment, incremental borrowing rate used in the calculation of right of use asset and lease liability, reserves for inventory, allowance for doubtful accounts, revenue allocations, valuation allowance on deferred tax assets, assumptions used in assessing impairment of long-term assets, assumptions used in the calculation of net realizable value of inventory and fair value of non-cash equity transactions.

Cash and Cash Equivalents

For purposes of balance sheet presentation and reporting of cash flows, the Company considers all unrestricted demand deposits, money market funds and highly liquid debt instruments with an original maturity of less than 90 days to be cash and cash equivalents. There were no cash equivalents. The Company places its cash and cash equivalents with high-quality financial institutions. At times, balances in the Company’s cash accounts may exceed the Federal Deposit Insurance Corporation (“FDIC”) limit. On March 31, 2024, the Company’s cash balances did not exceed the FDIC limit.

Accounts Receivable

Accounts receivable are generally unsecured. The Company establishes an allowance for doubtful accounts receivable based on the age of outstanding invoices and management’s evaluation of collectability. Accounts are written off after all reasonable collection efforts have been exhausted and management concludes that likelihood of collection is remote. Any future recoveries are applied against the allowance for doubtful accounts. An allowance of $50,000 was taken at the beginning of 2024 to allow for any doubtful accounts to be expensed. As of March 31, 2024, $0 of this allowance was expensed. The Company’s accounts receivable policy changed in 2021 to only provide larger, well-established companies with Net 30 payment terms. For all other sales they are paid by credit card or wires received before the product is shipped to the customer.

Inventory

Inventories are stated at lower of cost or net realizable value. Inventories of purchased materials are valued using a moving average method and managed on a first in first out basis (FIFO). Inventories of internally manufactured materials are valued using a standard costing method and are also managed on a FIFO basis. Production related costs that are capitalized as inventory as part of the standard cost valuation include the direct materials consumed, direct labor used, indirect labor used, and manufacturing overhead. Overhead is calculated based on specific manufacturing process and allocated on an order-by-order basis. Production variances that occur between standard cost valuation and actual costs are expensed as incurred in the income statement as part of cost of goods sold.

Marketable securities

The Company’s marketable securities consists of 79,200 shares of XXII which are classified as available-for-sale and included in current assets as they are pledged to secure two promissory notes. Securities are valued based on market prices for identical assets using third party certified pricing sources. Available-for-sale securities are carried at fair value with unrealized and realized gains and losses reported as a component of income (loss). Realized gains and losses, if any, are calculated on the specific identification method and are included in other income in the condensed consolidated statements of operations.

Fair Value Measurements

The Company adopted the provisions of Accounting Standard Codification (“ASC”) Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value, and expands disclosure of fair value measurements. The guidance prioritizes the inputs used in measuring fair value and establishes a three-tier value hierarchy that distinguishes among the following:

	●	Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.

	●	Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.

	●	Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The following table shows, by level within the fair value hierarchy, the Company’s assets and liabilities at fair value on a recurring basis as of March 31, 2024 and December 31, 2023:

	March 31, 2024								December 31, 2023
	Total		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3
Marketable securities	$	9,504		-	$	-		-	$	14,933	$	14,933	$	-	$	-
Total	$	9,504		-	$	-	$	-	$	14,933	$	14,933	$	-	$	-

	March 31, 2024
Balance at beginning of year	$	14,933
Realized loss on marketable securities, net		376
Unrealized loss on marketable securities, net		5,053
Balance at end of period	$	9,504

As of March 31, 2024, the Company has no liabilities that are re-measured at fair value.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method on the various asset classes over their estimated useful lives, which range from three to ten years when placed in service. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition.

Intangible Assets and Goodwill

Goodwill is comprised of the purchase price of business combinations in excess of the fair market value assigned at acquisition to the tangible and intangible assets acquired. Goodwill is not amortized. The Company tests goodwill for impairment on an annual basis. The Company performed its most recent goodwill impairment using a discounted cash flow analysis and found that the fair value exceeded the carrying value. It has $2.189 million of goodwill from the acquisition of the assets of Phoenix Life Sciences, Inc. in October 2017 and $0.825 million from the N7 acquisition.

		Estimated Life
Goodwill from Phoenix Acquisition		Tested Yearly for Impairment
Goodwill from N7 Acquisition		Tested Yearly for Impairment

	March 31, 2024		December 31, 2023
Goodwill from Phoenix Acquisition	$	2,188,810	$	2,188,810
Goodwill from N7 Acquisition		825,640		825,640
Total	$	3,014,450	$	3,014,450

Leases

The Company determines if an arrangement is a lease at inception. Contracts containing a lease are further evaluated for classification as an operating or finance lease. In determining the leases classification, the Company assesses among other criteria: (i) 75% or more of the remaining economic life of the underlying asset is a major part of the remaining economic life of that underlying asset; and (ii) 90% or more of the fair value of the underlying asset comprises substantially all of the fair value of the underlying asset. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities and long-term operating lease liabilities in the Company’s consolidated balance sheets. Finance leases are included in property, plant and equipment, net, other current liabilities, and long-term finance lease liabilities in the Company’s consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. For leases with terms greater than 12 months, the Company records the ROU asset and liability at commencement date based on the present value of lease payments according to their term.

The Company uses incremental borrowing rates based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expenses are recognized on a straight-line basis over the lease term or the useful life of the leased asset.

In addition, the carrying amount of the ROU and lease liabilities are remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset.

Convertible Notes Payable

The Company has previously issued convertible notes, which contain variable conversion features, whereby the outstanding principal and accrued interest automatically convert into common shares at a fixed price which may be a discount to the common stock at the time of conversion. Some of the conversion features of these notes are contingent upon future events, whereby, the holder agreed not to convert until the contingent future event has occurred. The Company currently does not hold any convertible notes.

Revenue Recognition

The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers.

The Company accounts for a contract when it has been approved and committed to, each party’s rights regarding the goods or services to be transferred have been identified, the payment terms have been identified, the contract has commercial substance, and collectability is probable. Revenue is generally recognized net of allowances for returns and any taxes collected from customers and subsequently remitted to governmental authorities. However, the Company’s sales are primarily through retail stores, purchase orders or ecommerce; thus, currently contract liabilities are negligible. The Company does not have any multiple-element arrangements.

Some of the Company’s contract liabilities consist of advance customer payments. Contract liability results from transactions in which the Company has been paid for products by customers, but for which all revenue recognition criteria have not yet been met. Once all revenue recognition criteria have been met, the contract liabilities are recognized. The Company recorded $400,955 and $349,705 in advanced customer payments as of March 31, 2024, and December 31, 2023, respectively, and these amounts are included in the balance sheet line item of accounts payable and accrued expenses.

	March 31, 2024		December 31, 2023
Balance, beginning of period	$	349,705	$	368,065
Payments received for unearned revenue		143,469		156,298
Revenue earned		92,219		174,658

Balance, end of period	$	400,955	$	349,705

Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

Revenue related to the sale of products is recognized once goods have been sold to the customer and the performance obligation has been completed. In both contracted purchase and retail sales, we offer consumer products through our online stores. Revenue is recognized when control of the goods is transferred to the customer. This generally occurs upon our delivery to a third-party carrier or, to the customer directly. Revenue from tolling services is recognized when the performance obligation, such as processing of the material, has been completed and output material has been transferred to the customer.

Revenue is generally recognized net of allowances for returns and any taxes collected from customers and subsequently remitted to governmental authorities. A contract liability results from transactions in which the Company has been paid for products by customers, but for which all revenue recognition criteria have not yet been met. Once all revenue recognition criteria have been met, the contract liabilities are recognized. The Company does not have any multiple-element arrangements.

The Company also has recorded other income related to rental income it receives from leasing out space in the laboratory it occupies.

Shipping and Handling Costs

The Company accounts for shipping and handling fees in accordance with ASC 606. The amounts charged to customers for shipping products are recognized as revenues and the related freight costs of shipping products are classified in general and administrative costs as incurred. Shipping costs are included as a component of general and administrative and were $9,566 and $29,667 for the three months ended March 31, 2024 and 2023, respectively.

Advertising & Marketing

Advertising costs are expensed when incurred and are included in advertising and promotional expense in the accompanying statements of operations. Included in this category are expenses related to public relations, investor relations, new package design, website design, design of promotional materials, cost of trade shows, cost of products given away as promotional samples, and paid advertising. The Company recorded advertising costs included in general and administrative costs of $2,486 and $8,769 for the three months ended March 31, 2024 and 2023, respectively.

Segment Information

The Company follows the provisions of ASC 280-10 Segment Reporting. This standard requires that companies disclose operating segments based on the manner in which management disaggregates the Company in making internal operating decisions. Segment identification and selection is consistent with the management structure used by the Company’s chief operating decision maker to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting, the Company has one operating segment. The Company’s chief operating decision maker does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviews operating results on an aggregate basis.

Earnings per Share

The Company computes basic and diluted earnings per share amounts in accordance with ASC Topic 260, “Earnings per Share”. Basic earnings per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per share reflects the potential dilution that could occur if preferred stock converted to common stock and warrants are exercised. Preferred stock and warrants are excluded from the diluted earnings per share calculation if their effect is anti-dilutive.

The following financial instruments were not included in the diluted loss per share calculation for the three months ended March 31, 2024 and 2023 because their effect was anti-dilutive:

	2024		2023
	For the three months ended March 31,
	2024		2023
Restricted stock		1,793,483		107,993
Options to purchase common stock		536,854		401,854
Warrants to purchase common stock		1,078,573		1,107,250
Series B-1 Convertible Preferred		6,679		6,679
Series B-2 Convertible Preferred		26,786		26,786
Series C Convertible Preferred		2,289,220		2,289,220
Series C-1 Convertible Preferred		1,064,908		1,064,908
Series D Convertible Preferred		1,628,126		1,628,126
Series E Convertible Preferred		3,853,000		-
Total		12,277,629		6,632,816
Anti-dilutive securities		12,277,629		6,632,816

Income Taxes

Income taxes are accounted for under the asset and liability method prescribed by FASB ASC Topic 740. These standards require a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more likely than not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax asset will not be realized.

Recently Issued Accounting Standards

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contract’s in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU simplifies the diluted net income per share calculation in certain areas. The ASU is effective for annual and interim periods beginning after December 31, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company does not expect the adoption of ASU 2020-6 to have any material impact on its consolidated financial statements.

In May 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-04 “Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation— Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815- 40) Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” which clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows: i) for a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged; ii) for all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged. The amendments in this Update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. The Company is currently evaluating the impact of this standard on its consolidated financial statements.

The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

NOTE 3 – PROPERTY, EQUIPMENT, NET OF ACCUMULATED DEPRECIATION

Property and equipment, net including any major improvements, are recorded at historical cost. The cost of repairs and maintenance is charged against operations as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets, generally as follows:

	Estimated Life
Computers and technological assets		3 – 5 Years
Furniture and fixtures		3 – 5 Years
Machinery and equipment		5 – 10 Years
Leasehold improvement		10 Years

Property and equipment, net consists of the following:

SCHEDULE OF PROPERTY AND EQUIPMENT

	March 31, 2024			December 31, 2023
Computers and technological assets	$	3,776,320		$	3,776,320
Furniture and fixtures		166,830			161,830
Machinery and equipment		7,846,788			7,846,788
Land		92,222			92,222
Leasehold improvements		1,806,755			1,806,755
Total		13,688,915			13,683,915
Less accumulated depreciation		(7,619,345	)		(7,235,847	)
Total property and equipment, net	$	6,069,570		$	6,448,068

Depreciation expenses for the three-month period ended March 31, 2024 and 2023 were $383,498 and $422,554 respectively.

NOTE 4 - INVENTORY

Inventory consists of the following components:

SCHEDULE OF INVENTORY

	March 31, 2024		December 31, 2023
Raw Materials	$	892,377	$	850,362
Semi-Finished		1,785,949		1,870,978
Finished Goods		1,358,063		1,262,674
Packaging		26,438		29,511
Total	$	4,062,827	$	4,013,525

Inventories are stated at lower of cost or net realizable value using the standard costing method for its work in process and finished goods. For its raw materials, trading goods, and packaging supplies, the Company utilizes the moving average method for costing purposes and FIFO. At this time there are no inventory reserves required.

NOTE 5 –OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES – RELATED PARTY

Right of Use

The Company adopted Accounting Standards Update (“ASU”) No. 2016-02, “Leases” (“ASC 842”) on January 1, 2019, the start of our 2019 fiscal year. The Company has one lease arrangement with a related party entered into on December 22, 2018 for 3-year term starting with January 1, 2019 for certain laboratory facilities, with a nine-year extension option. This lease was extended and now expires on December 31, 2030. At inception, the Company recognized a Right of Use Asset and a corresponding lease liability in the amount of $4,595,509. The Company’s lease arrangements may contain both lease and non-lease components. The Company has elected to combine and account for lease and non-lease components as a single lease component. The Company has incorporated residual value obligations in leases for which there is such occurrences. Regarding short-term leases, ASC 842-10-25-2 permits an entity to make a policy election not to apply the recognition requirements of ASC 842 to Short-term leases. The Company has elected not to apply the ASC 842 recognition criteria to any leases that qualify as Short-Term Leases.

The Company leases a portion of the property (formerly the Environmental Protection Agency building) in Golden, CO from J&N Real Estate, owned by the CEO, a related party with a term expiring on December 31, 2030. The lease consists of all laboratory space including testing facilities, water treatment, extraction and production. The lease of the property is based on the fair market rent and triple net lease (NNN) values competitive in the marketplace for a cGMP facility. The Company also subleases some of its laboratory space to other CBD companies. This income is presented under the Other Income line items of the statements of operations. The leases vary from short-term monthly leases to 3-year leases but are all cancellable.

Below is a summary of our right of use assets and liabilities as of March 31, 2024.

	March 31, 2024			December 31, 2023
Right-of-use assets	$	3,685,567		$	3,864591

Present value of operating lease liabilities	$	3,793,321		$	3,972,696
Less: Long-term portion of operating lease liability		(3,070,391	)		(3,254,021	)
Short-term portion of operating lease liability		722,930,			718,675
Unpaid balances		2,300,802			2,185,758
Total short-term lease liability obligations	$	3,023,732		$	2,904,433
Weighted-average remaining lease term (Ends December 31, 2030)		5.76 years			5.96 years

Weighted-average discount rate					3.0	%

During the three months ended March 31, 2024 and 2023, we recognized approximately $437,752 and $114,693 respectively in operating lease costs. Operating lease costs are included in operating expenses in our consolidated statement of operations.

Approximate future minimum lease payments for our right of use assets over the remaining lease periods as of March 31, 2024, are as follows:


2024		621,570
2025		830,307
2026		764,830
2027		474,122
Thereafter		1,451,002
Total undiscounted operating lease payments		4,141,831
Less: Imputed interest		(348,510	)
Present value of operating lease liabilities	$	3,793,321

NOTE 6 – NOTES PAYABLE

Paycheck Protection Program Funding U.S. Small Business Administration Loan

On May 28, 2020, the Company received a secured, 30-year, Economic Injury Disaster Loan in the amount of $99,100 from the U.S. Small Business Administration. The loan carries interest at a rate of 3.75% per year and matures in 30 years. The SBA loan is secured by a security interest in the Company’s tangible and intangible assets. As of March 31, 2024 the current principal balance of this note amounted to $99,100 and accrued interest was approximately $2,047.

Notes payable – related party and other liabilities.

As part of the Exchange Agreement certain loan balances (“J&N Loans”) from J&N Real Estate LLC, an affiliate of the Company’s CEO, (“J&N”) and historical interest owed of $1,932,358 were combined into a new promissory note with the principal amount of $4.062 million. The J&N Note bears annual interest at 12% and was secured by a pledge of certain XXII common stock owned by Panacea.

On June 30, 2021, the Company issued its CEO, Ms. Buttorff, a 10% promissory note in the amount of $1,685,685 (the “Buttorff Note”). This demand note replaced a prior working capital note that the Company had issued on January 1, 2021. On July 1, 2021, the Company issued Ms. Buttorff a 10%, $1 million line of credit note at 10% annual rate which Ms. Buttorff has since increased and has extended (see Note 6 – Notes Payable – Buttorff Note). The Company’s line of credit from Ms. Buttorff increased to $8,000,000 on July 1, 2022. The terms include an annual interest rate of 10% and a maturity date in 2025.

SCHEDULE OF NOTES PAYABLE RELATED PARTY

	March 31, 2024		December 31, 2023
J&N Note	$	4,062,713	$	4,062,713
CEO Note		7,709,546		7,334,904
Total related party notes	$	11,772,259	$	11,397,617

Other long-term liabilities, related party

The Company has recorded a related party liability (“Fixed Asset Loan”) in the amounts of $3,059,474 as of March 31, 2024 and December 31, 2023, respectively, relating to SAP software and support fees which were paid by an affiliate company of the CEO. The maturity date has not yet been determined. The Company is no longer paying any fees related to these services.

In 2020, the Company recorded an additional related party liability in the amount of $513,390 in respect to certain building improvements, due to J&N Real Estate Company (a company owned by the CEO) (“J&N Building Loan”). This balance bears no interest and the maturity date has not yet been determined.

SCHEDULE OF NOTES PAYABLE

	March 31, 2024		December 31, 2023
Other long-term liabilities, related party
Fixed Asset Loan	$	3,059,474	$	3,059,474
J&N Building Loan		513,390		513,390
Total	$	3,572,864	$	3,572,864

NOTE 7 - STOCKHOLDERS’ EQUITY

Common stock

The Company’s authorized common stock consists of 650,000,000 shares with a par value of $0.0001 per share.

During the three months ended March 31, 2024, the Company issued 666,000 shares of common stock in respect of the settlement of the convertible note payable.

Common stock options

Stock Option Plan

On June 30, 2021, the Company’s stockholders approved the 2021 Equity Incentive Plan (the “2021 Plan”). The 2021 Plan provided for the issuance of 4,049,409 incentive awards in the form of non-qualified and incentive stock options, restricted stock awards, restricted stock unit awards, warrants and preferred stock. The awards may be granted by the Company’s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company or to a subsidiary of the Company. The exercise price for stock options must not be less than the fair market value of the underlying shares on the date of grant. The incentive awards shall either be fully vested and exercisable from the date of grant or shall vest and become exercisable in such installments as the Board of Directors or Compensation Committee may specify. Stock options expire no later than ten years from the date of grant. Unless sooner terminated, the Plan shall terminate in 10 years.

This plan had 196,491 fully vested options outstanding at the time of the share exchange.

Stock Options

A summary of the stock option activity is presented below:

SCHEDULE OF STOCK OPTION ACTIVITY

	Options Outstanding as of March 31, 2024
	Number of Shares Subject to Options		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value

Balance on December 31, 2023		551,854	$	1.84		3.18	$	-
Options granted		-		-		-		-
Options exercised		-		-		-		-
Options canceled / expired		15,000		-		-		-
Balance on March 31, 2024		536,854	$	1.88		2.91	$	-

Vested and exercisable at March 31, 2024		196,491	$	1.88		2.91	$	-

The Company’s outstanding warrants as of March 31, 2024, are summarized as follows, and all were exercisable at that date.

SCHEDULE OF WARRANTS OUTSTANDING

	Warrants Outstanding as of March 31, 2024
	Number of Shares Subject to Warrants		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value

Balance on December 31, 2023		1,104,243	$	1.70		3.16		-
Options granted		-		-		-		-
Options exercised		-		-		-		-
Options canceled / expired		25,670		5.60		-		-
Balance at March 31, 2024		1,078,573	$	1.70		2.92	$	-

Vested and exercisable at March 31, 2024		1,078,573	$	1.70		2.92	$	-

As of March 31, 2024, the outstanding warrants had no intrinsic value.

Restricted Stock

A summary of the restricted stock activity is presented below:

SCHEDULE OF RESTRICTED STOCK

	Restricted Stock Common Stock
Balance at December 31, 2023		107,993
Balance at March 31, 2024		107,993

As of March 31, 2024, there were no unamortized or unvested stock-based compensation costs related to restricted share arrangements.

Preferred Stock

The Company’s authorized preferred stock consists of 50,000,000 shares with a par value of $0.0001.

On September 30, 2023, an asset purchase agreement with N7 Enterprises was closed. The original agreement was to award N7 785 shares of preferred E stock. Each share is convertible into 10,000 shares of common stock. The agreement contained a provision permitting the total number of shares to be adjusted based on projected sales targets being achieved. Due to these sales targets not being met, subsequent to the original award, the preferred shares were reduced to 385.

NOTE 8 - COMMITMENTS AND CONTINGENCIES

Legal Matters

In the ordinary course of business, the Company enters into agreements with third parties that include indemnification provisions which, in its judgment, are normal and customary for companies in the Company’s industry sector. These agreements are typically with business partners, and suppliers. Pursuant to these agreements, the Company generally agrees to indemnify, hold harmless, and reimburse indemnified parties for losses suffered or incurred by the indemnified parties with respect to the Company’s products, use of such products, or other actions taken or omitted by us. The maximum potential number of future payments the Company could be required to make under these indemnification provisions is unlimited. The Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of liabilities relating to these provisions is minimal. Accordingly, the Company has no liabilities recorded for these provisions as of March 31, 2024.

Concentrations

The Company has no contingencies, material commitments, purchase obligations, or sales obligations.

On the revenue side, in the three months ended March 31, 2024, we have a concentration of two customers.

Both are contract manufacturing customers who represent 46% and 13% of revenues. In the three months ended March 31, 2023, we had a concentration of two customers. Both are contract manufacturing customers who represent 31% and 13% of revenues.

The other concentration is in the accounts receivable category, where two customers account for 54% of total receivables. . One customer is unique in that we produced all of the products for them to sell, and they pay Panacea as the items are sold in the ecommerce marketplace. Thus, until their inventory is depleted, we will have accounts receivable. This customer receivable is 22% of the 54%. The other is a tenant who subleases space and accounts for 31% of the total receivables.

NOTE 9 - RELATED PARTY TRANSACTIONS

Notes Payable and Accrued Interest – Related Parties

For information on related party loans to the Company and other related party transactions, see Notes 5 and 6, Operating Lease and Notes Payable.

The accrued interest and interest expenses recorded for related party loans are shown below.

	March 31, 2024		December 31, 2023
Accrued Interest
Related party loan-J&N	$	1,579,136	$	1,413,210
Related party loan-CEO loan		531,044		476,536
Related party loan – Line of credit		1,164,347		964,486
Accrued Interest		1,164,347		964,486

	Three months ended March 31, 2024		Three months ended March 31, 2023
Interest Expense
Related party loan-J&N	$	165,926	$	147,251
Related party loan-CEO loan		54,507		49,341
Related party loan – Line of Credit		199,861		144,956
Interest Expense		199,861		144,956

NOTE 10– SUBSEQUENT EVENTS

None.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Business Overview

We are a Nevada corporation organized in 2008. Exactus, Inc. was our former name. We have pursued opportunities in hemp-based businesses, which we refer to as “cannabinoids or CBD”. On June 30, 2021 Panacea Life Sciences, Inc. “Panacea” entered into an Exchange Agreement with Exactus and as a result became a seed-to-sale Cannabinoid company. The former Panacea stockholders have assumed majority control of us and all our operations are now operated through Panacea which because of the share exchange became our wholly owned subsidiary. Leslie Buttorff, became our Chief Executive Officer and a director upon the closing of the share exchange, also became our principal stockholder through common stock and Convertible Preferred Stock issued to her and entities she controls.

Panacea Life Sciences Holdings, Inc. (PLSH) is holding company structured to support the life sciences and health and wellness industry. Panacea, which was founded by Leslie Buttorff in 2017 as a woman-owned business. Through Panacea, we are dedicated to developing and producing the highest-quality, most medically relevant, legal, hemp-derived cannabinoid products for consumers and pets. Beginning at a farm Panacea owns a parcel of located at Needle Rock, Colorado and leases laboratory space located within a 51,000 square foot, state-of-the-art, cGMP, extraction, manufacturing, testing and fulfillment center located in Golden, Colorado, Panacea operates in every segment of the CBD product value chain. From cultivation to finished goods, Panacea ensures its products with stringent testing protocols employed at every stage of the supply chain. Panacea endeavors to offer pure natural remedies within product lines for every aspect of life: PANA Life®, PANA Beauty®, PANA Sport™, PANA Pet® and PANA Health™. Currently Panacea sells over 50 different product SKUs of CBD and CBG products.

In late 2022 we shifted our focus to contract manufacturing for the nutraceutical industry. Its subsidiary, Panacea Life Sciences, Inc. (PLS) is dedicated to manufacturing, research and producing the highest-quality, hemp-derived cannabinoid, functional mushroom, Kratom and nutraceutical products for consumers and pets. From cultivation to finished goods, the company ensures its products with stringent GMP standards and testing protocols employed at every stage of the supply chain.

We are well positioned to develop novel extracts as dietary supplements and topical applications. Our biotechnology plans focus on our research at Colorado State University where we are involved in several health-related research studies.

We believe that our competitive advantages are derived from being vertically integrated that allows for extraction, enrichment and manufacturing under a cGMP quality environment: 1) Using pharmaceutical formulation methods to optimize the delivery of various products, and 2) utilize Good Manufacturing Practice to produce goods that are safe and quality products that deliver consistent dosing.

We are combining human and pet preclinical studies with Good Manufacturing Process manufacturing to generate a panel of products. Our products are formulated with delivery methods for health benefits including an intellectual property portfolio enabling development of topical creams, sublinguals, oral soft gel capsules, patches, and sprays.

Partnership with Universities

The grand opening of the Panacea Life Sciences Cannabinoid Research Center at Colorado State University was held on October 19, 2021. The first studies at the center are underway for isolation of rare cannabinoids, examining cannabidiol’s effects on Inflammatory Bowel Disease (IBS), canine and human dementia, as well as supporting research into chronic pelvic pain. These are all long-term, multi-year studies. We previously signed an agreement with the Colorado School of Mines in the area of developing hemp-based sustainability products.

Company Information Technology Infrastructure

The ERPCannabis system is based on an SAP architecture and was used to develop the base installation. All financial, human resource, payroll, procurement, production planning and materials management business processes are represented in this system. In addition, the system is linked to our e-Commerce website www.panacealife.com. This system allows us to update product costing and determine inventory levels which will be critical as the company expands. In addition, sophisticated financial and payroll processing are inherent in the solution; thus, offering investors detailed accounting results related to company investments. We plan to expand on the use of this infrastructure for acquisitions and service offerings.

Results of Operations

Set forth below is the discussion of the results of operations of the Company for the three months ended March 31, 2024, compared to the three months ended March 31, 2023. The information which follows relates to the operations of Panacea, which under applicable accounting rules are treated as the operation of the Company.

Three Months Ended March 31, 2024 and 2023

Net Revenues

In 2024 our revenues predominately came from contract manufacturing of nutraceutical products. Revenue consists of sales of our six category of brand products, white label and contract manufacturing sales to other companies, raw material sales (distillate and isolate), tolling products, and leasing space. We also have revenue from non-CBD nutraceutical companies.

Our revenues for the three months ended March 31, 2024, increased by $378,966, or 56%, to $1,056,447as compared to $677,481 for the three months ended March 31, 2023. The increase in sales in 2023 was due to an increase in manufacturing of non-CBD nutraceutical products.

Cost of Sales

Cost of sales for the three months ended March 31, 2024, decreased by $61,590 or 14% to 390,282 as compared to $451,872 for the three months ended March 31, 2023. The decrease in cost of sales was due primarily to lower raw material prices due to larger volume purchases for non-CBD contract manufacturing ingredients.

Operating Expenses

Operating expenses for the three months ended March 31, 2024, increased by $212,458, or 14%, to $1,728,030 as compared to $1,515,572 for the three months ended March 31, 2023. The increase in operating expenses is primarily due to increased production related operating expenses as well as increased general and administrative expenses.

Production related operating expenses for the three months ended March 31, 2024, increased by $216,316, or 17%, to 1,474,475 as compared to 1,258,159 during the three months ended March 31, 2023. The increase in production related operating expenses is primarily due to increased head count and increased labor costs.

General and administrative expenses for the three months ended March 31, 2024, decreased by $3,858, or 1%, to $ 353,555 as compared to $257,413during the three months ended March 31, 2023. This change is immaterial.

Other income (expense)

Other income (expense) for the three months ended March 31, 2024, decreased by $117,123 or 23% to ($384,209) as compared to ($501,332) for the three months ended March 31, 2023. The decrease in other income is primarily due to the unrealized loss of marketable securities held (XXII: NASDAQ).

Liquidity and Capital Resources

Cash flows from operating activities

The largest source of operating cash is from our customers. A large majority of our customers purchase CBD on-line, so credit card payments are collected and paid within 1-2 business days. Other white label and contract manufacturing customers pay before the products are released. Some larger customers have either net 10-, 2%- or 30-day net terms. Net cash used in operating activities was $357,090 and $313,851 for three months ended March 31 for 2024 and 2023, respectively. Approximately $0.854 million of our $1.446 million net loss in 2024 was non-cash.

Cash flows from investing activities

Cash outlay for the acquisition of fixed assets comprised the majority of this category and were $5,000 and $15,220 for the three months ended March 31, 2024, and 2023, respectively.

Cash flows from financing activities

Net cash provided by financing activities for the three months ended March 31, 2024 was $368,811. For the same period in 2023 the financing was $395,352. In both years the primary financing was cash provided by Company’s CEO.

Liquidity and Capital Resources

On March 31, 2024, we had $0.117 million in cash and liquid stock of XXII. Our Chief Executive Officer holds the XXII shares pursuant to the pledge agreement and has the power at any time to permit us to sell the shares to provide working capital. We have borrowed substantial sums from Leslie Buttorff, our Chief Executive Officer, to meet its working capital obligations. On June 30, 2021, Panacea issued an affiliate of Ms. Buttorff a 12% demand promissory note for $4.063 million and issued Ms. Buttorff a 10% demand promissory note for $1.624 million secured by a pledge of certain XXII common stock owned by Panacea. Additionally, we have a line of credit with Ms. Buttorff through which it may borrow up to $8 million at a 10% annual interest rate.

We do not have sufficient cash resources to sustain our operations for the next 12 months, particularly if the large sales agreements and purchase orders we have do not result in the revenue anticipated. We may be dependent on obtaining financing from one or more debt or equity offerings or further loans from Ms. Buttorff assuming she agrees to advance further funds.

These unaudited condensed consolidated financial statements are presented on the basis that the Company will continue as a going concern. The going concern concept contemplates the realization of assets and satisfaction of liabilities in the normal course of business. No adjustment has been made to the carrying amount and classification of the Company’s assets and the carrying amount of its liabilities based on the going concern uncertainty. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months from the issuance date of this report. Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive or raise additional debt and/or equity capital. In addition, due to insufficient revenue, we will need to obtain further funding through public or private equity offerings, debt financing, collaboration arrangements or other sources in order to maintain active business operations. We currently do not have sufficient cash flow to pay our ongoing financial obligations on a consistent basis. The issuance of any additional shares of common stock, preferred stock or convertible securities could be substantially dilutive to our stockholders. In addition, adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital, we will be forced to borrow additional sums from our Chief Executive Officer or delay, reduce or eliminate our research and development programs, we may not be able to continue as a going concern, and we may be forced to discontinue operations. These unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Off Balance Sheet Arrangements

As of March 31, 2024, we had no material off-balance sheet arrangements.

Potential Impacts of Certain Current and Proposed Regulations on Our Business and Operations

Recently, a bill titled the Cannabis Administration and Opportunity Act, put forward by Senate Majority leader Chuck Schumer, D-NY, would amend the definition of a dietary supplement to remove the prohibition on marketing CBD as a dietary supplement. Management sees the bill, if enacted, as an opportunity for the FDA to accelerate their decision to classify CBD products as a dietary supplement. This would be a significant step for hemp/CBD companies as it would open the door to new selling opportunities, such as getting into retail stores, who have largely been hesitant to welcome CBD in their doors without a clear position from the FDA.

Many people are increasingly turning to CBD products for several reasons: CBD is non-psychoactive, so it does not produce a “high” like THC, there are few known contraindications, the properties of different cannabinoids can positively affect a wide range of ailments, and cannabinoids work directly and indirectly with the body’s endocannabinoid system to create balance known as homeostasis. As demand increases, we believe the FDA must provide more clarity about CBD’s legalization, and this bill is a promising first step.

For now, many companies that produce hemp-derived CBD products including Panacea undertake to abide by the same regulations as any other dietary supplements like ingredient filings, good manufacturing practices (GMP), and labeling and marketing provisions. Panacea will continue to sell CBD and other hemp-derived products while still awaiting a clear path from the FDA about how CBD products can be marketed and used.

Cautionary Statement Regarding Forward-Looking Statements

This quarterly report on Form 10-Q (this “Report”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our new operations in the hemp industry through Panacea, our expected revenue growth, our human resources following our recent acquisition of Panacea, proposed federal legislation and its potential impact on the CBD industry, our plans to raise capital, and our liquidity. Words such as “expects,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “could,” “would,” “may,” “intends,” “targets” and similar expressions or variations of such words are intended to identify forward-looking statements but are not the exclusive means of identifying forward-looking statements in this Report. The identification of certain statements as “forward-looking” is not intended to mean that other statements not specifically identified are not forward-looking. All statements other than statements about historical facts are statements that could be deemed forward-looking statements, including, but not limited to, statements that relate to our future revenue, product development, customer demand, market acceptance, growth rate, competitiveness, gross margins, and expenditures.

Although forward-looking statements in this Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Further information on the risks and uncertainties affecting our business is contained in our filings with the SEC, including this Form 10-Q and our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. We undertake no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events or otherwise. Such risks, uncertainties and changes in condition, significance, value, and effect could cause our actual results to differ materially from those expressed herein and in ways not readily foreseeable. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Report and are based on information currently and reasonably known to us. We undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date of this Report, other than as required by law. Readers are urged to carefully review and consider the various disclosures made in this Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

Critical Accounting Estimates and New Accounting Pronouncements

New Accounting Pronouncements

See Note 2, SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES to the unaudited condensed consolidated financial statements contained in Part I, Item 1 of this amendment No. 1 to the Quarterly Report on Form 10-Q.

Critical Accounting Estimates

The discussion and analysis of the Company’s financial condition and results of operations is based upon the Company’s condensed consolidated financial statements, which have been prepared in accordance with US GAAP. The preparation of the Company’s condensed consolidated financial statements requires its management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses and related disclosures. The Company’s management bases its estimates, assumptions and judgments on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Different assumptions and judgments would change the estimates used in the preparation of the Company’s condensed consolidated financial statements which, in turn, could change the results from those reported. In addition, actual results may differ from these estimates and such differences could be material to the Company’s financial position and results of operations.

Critical accounting estimates are those that the Company’s management considers the most important to the portrayal of the Company’s financial condition and results of operations because they require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. The Company’s critical accounting estimates in relation to its condensed consolidated financial statements include those related to:

	●	Goodwill and intangible assets
	●	Fair value of marketable securities
	●	Incremental Borrowing Rate used Right of Use Asset Calculations
	●	Business combinations

Goodwill and Indefinite-Lived Intangibles

We allocate the cost of acquired companies to the identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount classified as goodwill. The identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition, as well as the completion of impairment tests, require significant management judgments and estimates. These estimates are made based on, among other factors, review of projected future operating results and business plans, economic projections, anticipated highest and best use of future cash flows and the cost of capital. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of goodwill and other intangible assets, and potentially result in a different impact to our results of operations. Further, changes in business strategy and/or market conditions may significantly impact these judgments and thereby impact the fair value of these assets, which could result in an impairment of the goodwill or intangible assets.

Goodwill is not amortized but is tested for impairment annually and whenever events or circumstances change that indicate impairment may have occurred. We tested goodwill for impairment and determined there was no impairment and found not impairment charge based on the excess of a reporting unit’s carrying amount over our fair value.

Fair value of marketable securities

Marketable securities are recorded at fair value using the quoted market prices and changes in fair value are recorded as net realized gains or losses in comprehensive income. We monitor these investments for impairment and make appropriate reductions in carrying values as necessary.

Incremental Borrowing Rate used Right of Use Asset Calculations

We determine if a contract is a lease or contains a lease at the inception of the contract and reassess that conclusion if the contract is modified. All leases are assessed for classification as an operating lease or a finance lease. Operating lease right-of-use, or ROU, assets are included in non-current other assets on our consolidated balance sheet. Operating lease liabilities are separated into a current portion, included within other accrued liabilities on our consolidated balance sheet, and a non-current portion, included within other long-term liabilities on our consolidated balance sheet. We do not have any finance lease ROU assets or liabilities. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. We do not obtain and control the right to use the identified asset until the lease commencement date.

Our lease liabilities are recognized at the applicable lease commencement date based on the present value of the lease payments required to be paid over the lease term. Because the interest rate implicit in the lease is not readily determinable, we generally use our incremental borrowing rate to discount the lease payments to present value. The estimated incremental borrowing rate is derived from information available at the lease commencement date. We factor in publicly available data for instruments with similar characteristics when calculating our incremental borrowing rates. Our ROU assets are also recognized at the applicable lease commencement date. The ROU asset equals the carrying amount of the related lease liability, adjusted for any lease payments made prior to lease commencement and lease incentives provided by the lessor. Variable lease payments are expensed as incurred and do not factor into the measurement of the applicable ROU asset or lease liability.

Business Combinations

We have applied significant estimates and judgments in order to determine the fair value of the identified assets acquired, liabilities assumed and goodwill recognized in connection with our business combinations to ensure the value of the assets and liabilities acquired are recognized at fair value as of the acquisition date. In measuring the fair value, we utilize valuation techniques consistent with the market approach, income approach, or cost approach.

The valuation of the identifiable assets and liabilities includes assumptions made in performing the valuation, such as projected revenue, weighted average cost of capital, discount rates, estimated useful lives, and other relevant assessments. These assessments can be significantly affected by our estimates, judgments, and assumptions. If actual results are not consistent with our estimates, judgments, or assumptions, or if additional or new information arises in the future that affects our fair value estimates, then adjustments to our initial fair value estimates may have a material impact to our purchase accounting or our results of operations. If actual results are not consistent with our estimates, judgments, or assumptions, or if additional or new information arises in the future, beyond our one-year measurement period, that affects our fair value estimates, then adjustments to our initial fair value estimates may have a material impact to our results of operations.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

A smaller reporting company is not required to provide the information required by this Item.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

Our management carried out an evaluation, with the participation of our Principal Executive Officer and Principal Financial Officer, required by Rule 13a-15 or 15d-15 of the Securities Exchange Act of 1934 (the “Exchange Act”) of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) or 15d-15(e) under the Exchange Act. Based on their evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures are effective as of the end of the period covered by this report to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

Except as noted above, there were no changes in our internal control over financial reporting as defined in Rule 13a-15(f) or 15d-15(f) under the Exchange Act that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

From time–to-time, we may become involved in legal proceedings arising in the ordinary course of business. We are unable to predict the outcome of any such matters or the ultimate legal and financial liability, and at this time cannot reasonably estimate the possible loss or gain or range of loss/gain and accordingly have not accrued a related liability.

ITEM 1A. RISK FACTORS.

Not applicable.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES OR USE OF PROCEEDS.

During the three months ended March 31, 2022, the Company Issued 123,334 shares of the Company’s common stock to the former Chief Strategy Officer of the Company in connection with the cashless exercise of stock options, as well as 447 shares the Company owed the former Chief Strategy Officer for inadvertently issuing less shares of common stock than the amount indicated on the Subscription Agreement dated January 18, 2019. The issuance of the shares was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) promulgated thereunder.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS.

		Incorporated by Reference			Filed or Furnished
Exhibit #	Exhibit Description	Form	Date	Number	Herewith
3.1	Amended Articles of Incorporation	8-K	7/7/21	3.1	Filed
3.2	Certificate of Amendment to its Amended and Restated Articles of Incorporation – name change and reverse stock split	8-K	10/29/21	3.1	Filed
3.3	Certificate of Designation for Series B-1 Preferred Stock	8-K	3/4/16	3.1	Filed
3.4	Certificate of Designation for Series B-2 Preferred Stock	8-K/A	2/17/16	3.2	Filed
3.5	Certificate of Designation for Series C Preferred Stock	10-Q	8/23/21	3.7	Filed
3.6	Certificate of Designation for Series C-1 Preferred Stock	10-Q	8/23/21	3.8	Filed
3.7	Certificate of Designation for Series C-2 Preferred Stock	8-K	10/29/21	3.2	Filed
3.8	Certificate of Designation for Series D Preferred Stock	10-Q	8/23/21	3.9	Filed
3.9	Certificate of Withdrawal for Series A Preferred Stock	10-K/A	4/29/22	3.10	Filed
3.10	Certificate of Designation for Series N-7 Convertible Preferred Stock	10-K	4/1/24	3.10	Filed
3.11	Amended and Restated Bylaws	10-K	3/30/23	3.2	Filed
4.1	Description of securities registered under Section 12 of the Exchange Act of 1934	10-K	3/30/23	4.1	Filed
10.1	Form of Exchange Agreement**	8-K	3/4/22	10.1	Filed
10.2	Form of Original Issue Discount Senior Convertible Promissory Note	8-K	3/4/22	10.2	Filed
10.3	Form of Warrant	8-K	3/4/22	10.3	Filed
10.4	Form of Registration Rights Agreement**	8-K	3/4/22	10.4
10.5	Share Exchange Agreement	8-K	2/18/21	10.2	Filed
10.6	Asset Purchase Agreement dated as of July 3, 2023**	8-K	7/10/23	10.1	Filed
10.7	Form of Pledge and Security Agreement	8-K	10/5/23	10.3	Filed
10.8	Form of Offset Agreement	8-K	10/5/23	10.5	Filed
10.9	Form of Leakout Agreement	8-K	10/5/23	10.6	Filed
10.10	Asset Purchase Agreement dated as of September 26, 2023	10-K	4/1/24	10.10	Filed
10.11	Release and Assignment Agreement dated November 10, 2023, by and between the Issuer and PUR Life Medical, Inc.	8-K	2/5/24	10.2	Filed

10.12	Asset Purchase Agreement dated January 29, 2024, by and between the Issuer and PLM Holdings, Inc.	8-K	2/5/24	10.3	Filed
10.13	Ex. 10.14 to 10-K__Form of Amendment No. 1 to Promissory Note dated March 5, 2024 by and between the Issuer and FirstFire Global Opportunities Fund LLC	10-K	4/1/24	10.13	Filed
10.14	Amended and Restated 2021 Equity Incentive Plan*	10-K	3/30/23	10.20	Filed
31.1	Certification of Principal Executive Officer and Principal Financial Officer (302)				Filed
32.1	Certification of Principal Executive and Principal Financial Officer (906)				Furnished***
101.INS	Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH	Inline XBRL Taxonomy Extension Schema Document				Filed
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document				Filed
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document				Filed
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document				Filed
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document				Filed
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Management contract or compensatory plan or arrangement.

** Exhibits and/or Schedules have been omitted. The Company hereby agrees to furnish to the Securities and Exchange Commission upon request any omitted information.

*** This exhibit is being furnished rather than filed and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-K.

+Portions of this exhibit have been omitted as permitted by the rules of the SEC. The information excluded is both (i) not material and (ii) the type that the Company customarily and actually treats as private or confidential. The Company undertakes to submit a marked copy of this exhibit for review by the SEC Staff, to the extent it has not been previously provided, and provide supplemental materials to the SEC Staff promptly upon request.

Copies of this Report (including the financial statements) and any of the exhibits referred to above will be furnished at no cost to our shareholders who make a written request to Panacea Life Sciences Holdings, Inc., at the address on the cover page of this Report, Attention: Corporate Secretary.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Panacea Life Sciences Holdings, Inc.

May 6, 2024	/s/ Leslie Buttorff
	Leslie Buttorff
	Chief Executive Officer

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

AND PRINCIPAL FINANCIAL OFFICER

I, Leslie Buttorff, certify that:

1. I have reviewed this Form 10-Q of Panacea Life Sciences Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 6, 2024

/s/ Leslie Buttorff
Leslie Buttorff
Chief Executive Officer and Chief Financial Officer
(Principal Executive Officer and Principal Financial Officer)

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Panacea Life Sciences Holdings, Inc. (the “Company”) Form 10-Q for the quarter ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Leslie Buttorff, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

	1.	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

	2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 6, 2024

/s/ Leslie Buttorff
Leslie Buttorff
Chief Executive Officer and Chief Financial Officer
(Principal Executive Officer and Principal Financial Officer)

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2024	May 01, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-38190
Entity Registrant Name	Panacea Life Sciences Holdings, Inc.
Entity Central Index Key	0001552189
Entity Tax Identification Number	27-1085858
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	5910 S University Blvd
Entity Address, Address Line Two	C18-193
Entity Address, City or Town	Greenwood Village
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80121
City Area Code	800
Local Phone Number	985-0515
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		17,645,352

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 107,643	$ 100,922
Accounts receivable, net	270,851	263,970
Inventory	4,062,827	4,013,525
Marketable securities related party	9,504	14,933
Prepaid expenses and other current assets	192,133	263,003
TOTAL CURRENT ASSETS	4,642,958	4,656,353
Operating lease right-of-use asset, net, related party	3,685,567	3,864,591
Property and equipment, net	6,069,570	6,448,068
Intangible assets, net
Goodwill	3,014,450	3,014,450
TOTAL ASSETS	17,412,545	17,983,462
CURRENT LIABILITIES:
Accounts payable and accrued expenses	5,178,214	4,629,591
Operating lease liability, current portion, related party	3,055,134	2,913,781
Convertible note payable, net		115,000
Paycheck protection loan, SBA Loan	99,100	99,100
TOTAL CURRENT LIABILITIES:	20,391,818	19,448,031
Operating lease liability, long-term portion, related party	3,070,391	3,254,021
Other long-term liabilities, related party	3,572,864	3,572,864
TOTAL LIABILITIES	27,035,073	26,274,916
Commitments and contingencies
STOCKHOLDERS’ EQUITY
Common Stock: $0.0001 Par Value, 650,000,000 shares authorized; 18,311,352 and 17,645,352 shares issued and outstanding on March 31, 2024 and December 31, 2023 respectively.	1,832	1,765
Additional paid in capital	25,743,375	25,628,442
Accumulated deficit	(35,368,972)	(33,922,898)
TOTAL STOCKHOLDERS’ EQUITY	(9,622,528)	(8,291,454)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	17,412,545	17,983,462
Series A Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Series E Preferred: $0.0001 Par Value, 3,853,000 shares designated and 3,853,000 and 3,853,000 shares issued and outstanding on March 31, 2024 and December 31, 2023 respectively.
Series B-1 Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Series E Preferred: $0.0001 Par Value, 3,853,000 shares designated and 3,853,000 and 3,853,000 shares issued and outstanding on March 31, 2024 and December 31, 2023 respectively.	150	150
Series B-2 Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Series E Preferred: $0.0001 Par Value, 3,853,000 shares designated and 3,853,000 and 3,853,000 shares issued and outstanding on March 31, 2024 and December 31, 2023 respectively.	600	600
Series C Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Series E Preferred: $0.0001 Par Value, 3,853,000 shares designated and 3,853,000 and 3,853,000 shares issued and outstanding on March 31, 2024 and December 31, 2023 respectively.	100	100
Series C-1 Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Series E Preferred: $0.0001 Par Value, 3,853,000 shares designated and 3,853,000 and 3,853,000 shares issued and outstanding on March 31, 2024 and December 31, 2023 respectively.	1	1
Series C-2 preferred stock [Member]
STOCKHOLDERS’ EQUITY
Series E Preferred: $0.0001 Par Value, 3,853,000 shares designated and 3,853,000 and 3,853,000 shares issued and outstanding on March 31, 2024 and December 31, 2023 respectively.
Series D Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Series E Preferred: $0.0001 Par Value, 3,853,000 shares designated and 3,853,000 and 3,853,000 shares issued and outstanding on March 31, 2024 and December 31, 2023 respectively.	1	1
Series E Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Series E Preferred: $0.0001 Par Value, 3,853,000 shares designated and 3,853,000 and 3,853,000 shares issued and outstanding on March 31, 2024 and December 31, 2023 respectively.	385	385
Related Party [Member]
CURRENT ASSETS:
Other receivables, related party
CURRENT LIABILITIES:
First Bank note payable	11,772,259	11,397,617
Nonrelated Party [Member]
CURRENT LIABILITIES:
First Bank note payable	$ 287,111	$ 292,942

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Preferred stock, par value	$ 0.0001
Preferred stock, shares designated	50,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	650,000,000	650,000,000
Common stock, shares issued	18,311,352	17,645,352
Common stock, shares outstanding	18,311,352	17,645,352
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares designated	1,000	1,000
Preferred stock, shares issued	0	350
Preferred stock, shares outstanding	0	350
Series B-1 Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares designated	32,000,000	32,000,000
Preferred stock, shares issued	1,500,000	1,500,000
Preferred stock, shares outstanding	1,500,000	1,500,000
Series B-2 Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares designated	6,000,000	6,000,000
Preferred stock, shares issued	6,000,000	6,000,000
Preferred stock, shares outstanding	6,000,000	6,000,000
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares designated	1,000,000	1,000,000
Preferred stock, shares issued	1,000,000	1,000,000
Preferred stock, shares outstanding	1,000,000	1,000,000
Series C-1 Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares designated	10,000	10,000
Preferred stock, shares issued	10,000	10,000
Preferred stock, shares outstanding	10,000	10,000
Series C-2 preferred stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares designated	100	0
Preferred stock, shares issued	100	0
Preferred stock, shares outstanding	100	0
Series D Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares designated	10,000	10,000
Preferred stock, shares issued	10,000	10,000
Preferred stock, shares outstanding	10,000	10,000
Series E Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares designated	3,853,000	3,853,000
Preferred stock, shares issued	3,853,000	3,853,000
Preferred stock, shares outstanding	3,853,000	3,853,000

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
REVENUE	$ 1,056,447	$ 677,481
COST OF SALES	390,282	451,872
GROSS PROFIT	666,165	225,609
OPERATING EXPENSES
Production related operating expenses	1,474,475	1,258,159
General and administrative expenses	249,038	257,413
TOTAL OPERATING EXPENSES	1,723,513	1,515,572
LOSS FROM OPERATIONS	(1,057,348)	(1,289,963)
OTHER INCOME (EXPENSES)
Interest expense	(429,672)	(380,157)
Unrealized gain (loss) on marketable securities, net	5,053	(182,255)
Realized gain (loss) on sale of securities	(376)
Other income (loss)
Employer retention credit
Rental Income	36,269	60,332
Gain on extinguishment of debt		748
TOTAL OTHER INCOME (EXPENSE)	(388,726)	(501,332)
INCOME (LOSS) BEFORE INCOME TAXES	(1,446,074)	(1,791,295)
TAXES
NET INCOME (LOSS)	$ (1,446,074)	$ (1,791,295)
Per-share data
Basic loss per share	$ (0.09)	$ (0.12)
Diluted loss per share	$ (0.09)	$ (0.12)
Weighted average number of common shares outstanding, basic	16,492,589	14,965,317
Weighted average number of common shares outstanding, diluted	16,492,589	14,965,317

Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022	$ 853	$ 1,497	$ 23,760,704	$ (25,907,597)	$ (2,144,544)
Balance, shares at Dec. 31, 2022	8,530,000	14,965,317
Shares issued in respect of the merger
Shares issued in settlement of convertible note		$ 54	134,946		135,000
Shares issued in settlement of convertible note, shares		540,000
Net Loss				(1,791,295)	(1,791,295)
Issuance of common shares for services
Balance at Mar. 31, 2023	$ 853	$ 1,551	23,895,650	(27,698,892)	(3,800,839)
Balance, shares at Mar. 31, 2023	8,530,000	15,505,317
Balance at Dec. 31, 2023	$ 1,238	$ 1,765	25,628,442	(33,922,898)	(8,291,454)
Balance, shares at Dec. 31, 2023	12,838,350	17,645,352
Shares issued in respect of the merger
Shares issued in settlement of convertible note		$ 67	114,933		115,000
Shares issued in settlement of convertible note, shares		666,000
Net Loss					(1,446,074)
Balance at Mar. 31, 2024	$ 1,238	$ 1,832	$ 25,743,375	$ (33,922,898)	$ (9,622,528)
Balance, shares at Mar. 31, 2024	12,838,350	18,311,352

Statements of Cash Flows - USD ($)	3 Months Ended
Statements of Cash Flows - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities
Net income (loss)	$ (1,446,074)	$ (1,791,295)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	383,498	422,554
Realized gain on sale of securities	376
Unrealized (gain)/loss on marketable securities	5,053	182,255
Amortization of debt discount and non-cash interest expense		38,329
Changes in operating assets and liabilities
Accounts receivable	(6,881)	(68,660)
Inventory	(49,302)	353,662
Prepaid expense and other assets	70,870	34,552
Accounts payable and accrued expenses	548,623	400,059
Operating lease liability, net	136,747	114,693
Net cash used in operating activities	(357,090)	(313,851)
Cash flows from investing activities
Net fixed asset acquisitions	(5,000)	(15,220)
Net Cash provided by (used in) investing activities	(5,000)	(15,220)
Cash flows from financing activities
Repayment of notes payable	(5,831)	(135,000)
Payments of principal on notes payable – related party	(74,000)	(65,000)
Proceeds from Notes payable - related party	448,642	595,352
Cash provided by financing activities	368,811	395,352
Net increase (decrease) in Cash and Cash Equivalents	6,721	66,281
Cash and Cash Equivalents, Beginning of Period	100,922	6,951
Cash and Cash Equivalents, End of Period	107,643	73,232
Supplemental Disclosure of Cash Flow Information
Cash paid for income taxes during the year
Interest payments during the year
Noncash investing and financing activity
Conversion of note payable to common stock	$ (115,000)

NATURE OF ORGANIZATION

3 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF ORGANIZATION

NOTE 1 - NATURE OF ORGANIZATION

Organization and Business Description

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation and principles of consolidation

The Company’s consolidated financial statements include the financial statements of Panacea Life Sciences, Inc.

Going concern

Use of Estimates

Cash and Cash Equivalents

Accounts Receivable

Inventory

Marketable securities

Fair Value Measurements

	●	Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.

	●	Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.

	●	Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The following table shows, by level within the fair value hierarchy, the Company’s assets and liabilities at fair value on a recurring basis as of March 31, 2024 and December 31, 2023:

	March 31, 2024								December 31, 2023
	Total		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3
Marketable securities	$	9,504		-	$	-		-	$	14,933	$	14,933	$	-	$	-
Total	$	9,504		-	$	-	$	-	$	14,933	$	14,933	$	-	$	-

	March 31, 2024
Balance at beginning of year	$	14,933
Realized loss on marketable securities, net		376
Unrealized loss on marketable securities, net		5,053
Balance at end of period	$	9,504

As of March 31, 2024, the Company has no liabilities that are re-measured at fair value.

Property and Equipment

Intangible Assets and Goodwill

		Estimated Life
Goodwill from Phoenix Acquisition		Tested Yearly for Impairment
Goodwill from N7 Acquisition		Tested Yearly for Impairment

	March 31, 2024		December 31, 2023
Goodwill from Phoenix Acquisition	$	2,188,810	$	2,188,810
Goodwill from N7 Acquisition		825,640		825,640
Total	$	3,014,450	$	3,014,450

Leases

Convertible Notes Payable

Revenue Recognition

The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers.

	March 31, 2024		December 31, 2023
Balance, beginning of period	$	349,705	$	368,065
Payments received for unearned revenue		143,469		156,298
Revenue earned		92,219		174,658

Balance, end of period	$	400,955	$	349,705

The Company also has recorded other income related to rental income it receives from leasing out space in the laboratory it occupies.

Shipping and Handling Costs

Advertising & Marketing

Segment Information

Earnings per Share

The following financial instruments were not included in the diluted loss per share calculation for the three months ended March 31, 2024 and 2023 because their effect was anti-dilutive:

	2024		2023
	For the three months ended March 31,
	2024		2023
Restricted stock		1,793,483		107,993
Options to purchase common stock		536,854		401,854
Warrants to purchase common stock		1,078,573		1,107,250
Series B-1 Convertible Preferred		6,679		6,679
Series B-2 Convertible Preferred		26,786		26,786
Series C Convertible Preferred		2,289,220		2,289,220
Series C-1 Convertible Preferred		1,064,908		1,064,908
Series D Convertible Preferred		1,628,126		1,628,126
Series E Convertible Preferred		3,853,000		-
Total		12,277,629		6,632,816
Anti-dilutive securities		12,277,629		6,632,816

Income Taxes

Recently Issued Accounting Standards

The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

PROPERTY, EQUIPMENT, NET OF ACCUMULATED DEPRECIATION

3 Months Ended

Mar. 31, 2024

Property, Plant and Equipment [Abstract]

PROPERTY, EQUIPMENT, NET OF ACCUMULATED DEPRECIATION

NOTE 3 – PROPERTY, EQUIPMENT, NET OF ACCUMULATED DEPRECIATION

	Estimated Life
Computers and technological assets		3 – 5 Years
Furniture and fixtures		3 – 5 Years
Machinery and equipment		5 – 10 Years
Leasehold improvement		10 Years

Property and equipment, net consists of the following:

SCHEDULE OF PROPERTY AND EQUIPMENT

	March 31, 2024			December 31, 2023
Computers and technological assets	$	3,776,320		$	3,776,320
Furniture and fixtures		166,830			161,830
Machinery and equipment		7,846,788			7,846,788
Land		92,222			92,222
Leasehold improvements		1,806,755			1,806,755
Total		13,688,915			13,683,915
Less accumulated depreciation		(7,619,345	)		(7,235,847	)
Total property and equipment, net	$	6,069,570		$	6,448,068

Depreciation expenses for the three-month period ended March 31, 2024 and 2023 were $383,498 and $422,554 respectively.

INVENTORY

3 Months Ended

Mar. 31, 2024

Inventory Disclosure [Abstract]

INVENTORY

NOTE 4 - INVENTORY

Inventory consists of the following components:

SCHEDULE OF INVENTORY

	March 31, 2024		December 31, 2023
Raw Materials	$	892,377	$	850,362
Semi-Finished		1,785,949		1,870,978
Finished Goods		1,358,063		1,262,674
Packaging		26,438		29,511
Total	$	4,062,827	$	4,013,525

OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES – RELATED PARTY

3 Months Ended

Mar. 31, 2024

Operating Lease Right-of-use Assets And Operating Lease Liabilities Related Party

OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES – RELATED PARTY

NOTE 5 –OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES – RELATED PARTY

Right of Use

Below is a summary of our right of use assets and liabilities as of March 31, 2024.

	March 31, 2024			December 31, 2023
Right-of-use assets	$	3,685,567		$	3,864591

Present value of operating lease liabilities	$	3,793,321		$	3,972,696
Less: Long-term portion of operating lease liability		(3,070,391	)		(3,254,021	)
Short-term portion of operating lease liability		722,930,			718,675
Unpaid balances		2,300,802			2,185,758
Total short-term lease liability obligations	$	3,023,732		$	2,904,433
Weighted-average remaining lease term (Ends December 31, 2030)		5.76 years			5.96 years

Weighted-average discount rate					3.0	%

Approximate future minimum lease payments for our right of use assets over the remaining lease periods as of March 31, 2024, are as follows:


2024		621,570
2025		830,307
2026		764,830
2027		474,122
Thereafter		1,451,002
Total undiscounted operating lease payments		4,141,831
Less: Imputed interest		(348,510	)
Present value of operating lease liabilities	$	3,793,321

NOTES PAYABLE

3 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

NOTES PAYABLE

NOTE 6 – NOTES PAYABLE

Paycheck Protection Program Funding U.S. Small Business Administration Loan

Notes payable – related party and other liabilities.

SCHEDULE OF NOTES PAYABLE RELATED PARTY

	March 31, 2024		December 31, 2023
J&N Note	$	4,062,713	$	4,062,713
CEO Note		7,709,546		7,334,904
Total related party notes	$	11,772,259	$	11,397,617

Other long-term liabilities, related party

SCHEDULE OF NOTES PAYABLE

	March 31, 2024		December 31, 2023
Other long-term liabilities, related party
Fixed Asset Loan	$	3,059,474	$	3,059,474
J&N Building Loan		513,390		513,390
Total	$	3,572,864	$	3,572,864

STOCKHOLDERS’ EQUITY

3 Months Ended

Mar. 31, 2024

Equity [Abstract]

STOCKHOLDERS’ EQUITY

NOTE 7 - STOCKHOLDERS’ EQUITY

Common stock

The Company’s authorized common stock consists of 650,000,000 shares with a par value of $0.0001 per share.

During the three months ended March 31, 2024, the Company issued 666,000 shares of common stock in respect of the settlement of the convertible note payable.

Common stock options

Stock Option Plan

This plan had 196,491 fully vested options outstanding at the time of the share exchange.

Stock Options

A summary of the stock option activity is presented below:

SCHEDULE OF STOCK OPTION ACTIVITY

	Options Outstanding as of March 31, 2024
	Number of Shares Subject to Options		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value

Balance on December 31, 2023		551,854	$	1.84		3.18	$	-
Options granted		-		-		-		-
Options exercised		-		-		-		-
Options canceled / expired		15,000		-		-		-
Balance on March 31, 2024		536,854	$	1.88		2.91	$	-

Vested and exercisable at March 31, 2024		196,491	$	1.88		2.91	$	-

The Company’s outstanding warrants as of March 31, 2024, are summarized as follows, and all were exercisable at that date.

SCHEDULE OF WARRANTS OUTSTANDING

	Warrants Outstanding as of March 31, 2024
	Number of Shares Subject to Warrants		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value

Balance on December 31, 2023		1,104,243	$	1.70		3.16		-
Options granted		-		-		-		-
Options exercised		-		-		-		-
Options canceled / expired		25,670		5.60		-		-
Balance at March 31, 2024		1,078,573	$	1.70		2.92	$	-

Vested and exercisable at March 31, 2024		1,078,573	$	1.70		2.92	$	-

As of March 31, 2024, the outstanding warrants had no intrinsic value.

Restricted Stock

A summary of the restricted stock activity is presented below:

SCHEDULE OF RESTRICTED STOCK

	Restricted Stock Common Stock
Balance at December 31, 2023		107,993
Balance at March 31, 2024		107,993

As of March 31, 2024, there were no unamortized or unvested stock-based compensation costs related to restricted share arrangements.

Preferred Stock

The Company’s authorized preferred stock consists of 50,000,000 shares with a par value of $0.0001.

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 8 - COMMITMENTS AND CONTINGENCIES

Legal Matters

Concentrations

The Company has no contingencies, material commitments, purchase obligations, or sales obligations.

On the revenue side, in the three months ended March 31, 2024, we have a concentration of two customers.

RELATED PARTY TRANSACTIONS

3 Months Ended

Mar. 31, 2024

RELATED PARTY TRANSACTIONS

NOTE 9 - RELATED PARTY TRANSACTIONS

Notes Payable and Accrued Interest – Related Parties

For information on related party loans to the Company and other related party transactions, see Notes 5 and 6, Operating Lease and Notes Payable.

The accrued interest and interest expenses recorded for related party loans are shown below.

	March 31, 2024		December 31, 2023
Accrued Interest
Related party loan-J&N	$	1,579,136	$	1,413,210
Related party loan-CEO loan		531,044		476,536
Related party loan – Line of credit		1,164,347		964,486
Accrued Interest		1,164,347		964,486

	Three months ended March 31, 2024		Three months ended March 31, 2023
Interest Expense
Related party loan-J&N	$	165,926	$	147,251
Related party loan-CEO loan		54,507		49,341
Related party loan – Line of Credit		199,861		144,956
Interest Expense		199,861		144,956

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2024

Subsequent Events

SUBSEQUENT EVENTS

NOTE 10– SUBSEQUENT EVENTS

None.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Basis of presentation and principles of consolidation

Basis of presentation and principles of consolidation

The Company’s consolidated financial statements include the financial statements of Panacea Life Sciences, Inc.

Going concern

Going concern

Use of Estimates

Use of Estimates

Cash and Cash Equivalents

Cash and Cash Equivalents

Accounts Receivable

Accounts Receivable

Inventory

Inventory

Marketable securities

Marketable securities

Fair Value Measurements

Fair Value Measurements

	●	Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.

	●	Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.

	●	Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The following table shows, by level within the fair value hierarchy, the Company’s assets and liabilities at fair value on a recurring basis as of March 31, 2024 and December 31, 2023:

	March 31, 2024								December 31, 2023
	Total		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3
Marketable securities	$	9,504		-	$	-		-	$	14,933	$	14,933	$	-	$	-
Total	$	9,504		-	$	-	$	-	$	14,933	$	14,933	$	-	$	-

	March 31, 2024
Balance at beginning of year	$	14,933
Realized loss on marketable securities, net		376
Unrealized loss on marketable securities, net		5,053
Balance at end of period	$	9,504

As of March 31, 2024, the Company has no liabilities that are re-measured at fair value.

Property and Equipment

Property and Equipment

Intangible Assets and Goodwill

Intangible Assets and Goodwill

		Estimated Life
Goodwill from Phoenix Acquisition		Tested Yearly for Impairment
Goodwill from N7 Acquisition		Tested Yearly for Impairment

	March 31, 2024		December 31, 2023
Goodwill from Phoenix Acquisition	$	2,188,810	$	2,188,810
Goodwill from N7 Acquisition		825,640		825,640
Total	$	3,014,450	$	3,014,450

Leases

Leases

Convertible Notes Payable

Convertible Notes Payable

Revenue Recognition

Revenue Recognition

The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers.

	March 31, 2024		December 31, 2023
Balance, beginning of period	$	349,705	$	368,065
Payments received for unearned revenue		143,469		156,298
Revenue earned		92,219		174,658

Balance, end of period	$	400,955	$	349,705

The Company also has recorded other income related to rental income it receives from leasing out space in the laboratory it occupies.

Shipping and Handling Costs

Shipping and Handling Costs

Advertising & Marketing

Advertising & Marketing

Segment Information

Segment Information

Earnings per Share

Earnings per Share

The following financial instruments were not included in the diluted loss per share calculation for the three months ended March 31, 2024 and 2023 because their effect was anti-dilutive:

	2024		2023
	For the three months ended March 31,
	2024		2023
Restricted stock		1,793,483		107,993
Options to purchase common stock		536,854		401,854
Warrants to purchase common stock		1,078,573		1,107,250
Series B-1 Convertible Preferred		6,679		6,679
Series B-2 Convertible Preferred		26,786		26,786
Series C Convertible Preferred		2,289,220		2,289,220
Series C-1 Convertible Preferred		1,064,908		1,064,908
Series D Convertible Preferred		1,628,126		1,628,126
Series E Convertible Preferred		3,853,000		-
Total		12,277,629		6,632,816
Anti-dilutive securities		12,277,629		6,632,816

Income Taxes

Income Taxes

Recently Issued Accounting Standards

Recently Issued Accounting Standards

The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

SCHEDULE OF FAIR VALUE ASSETS MEASURED ON RECURRING BASIS

The following table shows, by level within the fair value hierarchy, the Company’s assets and liabilities at fair value on a recurring basis as of March 31, 2024 and December 31, 2023:

	March 31, 2024								December 31, 2023
	Total		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3
Marketable securities	$	9,504		-	$	-		-	$	14,933	$	14,933	$	-	$	-
Total	$	9,504		-	$	-	$	-	$	14,933	$	14,933	$	-	$	-

SCHEDULE OF MARKETABLE SECURITIES

	March 31, 2024
Balance at beginning of year	$	14,933
Realized loss on marketable securities, net		376
Unrealized loss on marketable securities, net		5,053
Balance at end of period	$	9,504

SCHEDULE OF INTANGIBLE ASSETS AND GOODWILL

		Estimated Life
Goodwill from Phoenix Acquisition		Tested Yearly for Impairment
Goodwill from N7 Acquisition		Tested Yearly for Impairment

	March 31, 2024		December 31, 2023
Goodwill from Phoenix Acquisition	$	2,188,810	$	2,188,810
Goodwill from N7 Acquisition		825,640		825,640
Total	$	3,014,450	$	3,014,450

SCHEDULE OF REVENUE FROM CONTRACT WITH CUSTOMER

	March 31, 2024		December 31, 2023
Balance, beginning of period	$	349,705	$	368,065
Payments received for unearned revenue		143,469		156,298
Revenue earned		92,219		174,658

Balance, end of period	$	400,955	$	349,705

SCHEDULE OF ANTI-DILUTIVE DILUTED LOSS PER SHARE

The following financial instruments were not included in the diluted loss per share calculation for the three months ended March 31, 2024 and 2023 because their effect was anti-dilutive:

	2024		2023
	For the three months ended March 31,
	2024		2023
Restricted stock		1,793,483		107,993
Options to purchase common stock		536,854		401,854
Warrants to purchase common stock		1,078,573		1,107,250
Series B-1 Convertible Preferred		6,679		6,679
Series B-2 Convertible Preferred		26,786		26,786
Series C Convertible Preferred		2,289,220		2,289,220
Series C-1 Convertible Preferred		1,064,908		1,064,908
Series D Convertible Preferred		1,628,126		1,628,126
Series E Convertible Preferred		3,853,000		-
Total		12,277,629		6,632,816
Anti-dilutive securities		12,277,629		6,632,816

PROPERTY, EQUIPMENT, NET OF ACCUMULATED DEPRECIATION (Tables)

3 Months Ended

Mar. 31, 2024

Property, Plant and Equipment [Abstract]

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT USEFUL LIVES

	Estimated Life
Computers and technological assets		3 – 5 Years
Furniture and fixtures		3 – 5 Years
Machinery and equipment		5 – 10 Years
Leasehold improvement		10 Years

SCHEDULE OF PROPERTY AND EQUIPMENT

Property and equipment, net consists of the following:

SCHEDULE OF PROPERTY AND EQUIPMENT

	March 31, 2024			December 31, 2023
Computers and technological assets	$	3,776,320		$	3,776,320
Furniture and fixtures		166,830			161,830
Machinery and equipment		7,846,788			7,846,788
Land		92,222			92,222
Leasehold improvements		1,806,755			1,806,755
Total		13,688,915			13,683,915
Less accumulated depreciation		(7,619,345	)		(7,235,847	)
Total property and equipment, net	$	6,069,570		$	6,448,068

INVENTORY (Tables)

3 Months Ended

Mar. 31, 2024

Inventory Disclosure [Abstract]

SCHEDULE OF INVENTORY

Inventory consists of the following components:

SCHEDULE OF INVENTORY

	March 31, 2024		December 31, 2023
Raw Materials	$	892,377	$	850,362
Semi-Finished		1,785,949		1,870,978
Finished Goods		1,358,063		1,262,674
Packaging		26,438		29,511
Total	$	4,062,827	$	4,013,525

OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES – RELATED PARTY (Tables)

3 Months Ended

Mar. 31, 2024

Operating Lease Right-of-use Assets And Operating Lease Liabilities Related Party

SCHEDULE OF RIGHT OF USE ASSET AND LIABILITY

Below is a summary of our right of use assets and liabilities as of March 31, 2024.

	March 31, 2024			December 31, 2023
Right-of-use assets	$	3,685,567		$	3,864591

Present value of operating lease liabilities	$	3,793,321		$	3,972,696
Less: Long-term portion of operating lease liability		(3,070,391	)		(3,254,021	)
Short-term portion of operating lease liability		722,930,			718,675
Unpaid balances		2,300,802			2,185,758
Total short-term lease liability obligations	$	3,023,732		$	2,904,433
Weighted-average remaining lease term (Ends December 31, 2030)		5.76 years			5.96 years

Weighted-average discount rate					3.0	%

SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITIES

Approximate future minimum lease payments for our right of use assets over the remaining lease periods as of March 31, 2024, are as follows:


2024		621,570
2025		830,307
2026		764,830
2027		474,122
Thereafter		1,451,002
Total undiscounted operating lease payments		4,141,831
Less: Imputed interest		(348,510	)
Present value of operating lease liabilities	$	3,793,321

NOTES PAYABLE (Tables)

3 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

SCHEDULE OF NOTES PAYABLE RELATED PARTY

	March 31, 2024		December 31, 2023
J&N Note	$	4,062,713	$	4,062,713
CEO Note		7,709,546		7,334,904
Total related party notes	$	11,772,259	$	11,397,617

SCHEDULE OF NOTES PAYABLE

	March 31, 2024		December 31, 2023
Other long-term liabilities, related party
Fixed Asset Loan	$	3,059,474	$	3,059,474
J&N Building Loan		513,390		513,390
Total	$	3,572,864	$	3,572,864

STOCKHOLDERS’ EQUITY (Tables)

3 Months Ended

Mar. 31, 2024

Equity [Abstract]

SCHEDULE OF STOCK OPTION ACTIVITY

A summary of the stock option activity is presented below:

SCHEDULE OF STOCK OPTION ACTIVITY

	Options Outstanding as of March 31, 2024
	Number of Shares Subject to Options		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value

Balance on December 31, 2023		551,854	$	1.84		3.18	$	-
Options granted		-		-		-		-
Options exercised		-		-		-		-
Options canceled / expired		15,000		-		-		-
Balance on March 31, 2024		536,854	$	1.88		2.91	$	-

Vested and exercisable at March 31, 2024		196,491	$	1.88		2.91	$	-

SCHEDULE OF WARRANTS OUTSTANDING

The Company’s outstanding warrants as of March 31, 2024, are summarized as follows, and all were exercisable at that date.

SCHEDULE OF WARRANTS OUTSTANDING

	Warrants Outstanding as of March 31, 2024
	Number of Shares Subject to Warrants		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value

Balance on December 31, 2023		1,104,243	$	1.70		3.16		-
Options granted		-		-		-		-
Options exercised		-		-		-		-
Options canceled / expired		25,670		5.60		-		-
Balance at March 31, 2024		1,078,573	$	1.70		2.92	$	-

Vested and exercisable at March 31, 2024		1,078,573	$	1.70		2.92	$	-

SCHEDULE OF RESTRICTED STOCK

A summary of the restricted stock activity is presented below:

SCHEDULE OF RESTRICTED STOCK

	Restricted Stock Common Stock
Balance at December 31, 2023		107,993
Balance at March 31, 2024		107,993

RELATED PARTY TRANSACTIONS (Tables)

3 Months Ended

Mar. 31, 2024

The accrued interest and interest expenses recorded for related party loans are shown below.

	March 31, 2024		December 31, 2023
Accrued Interest
Related party loan-J&N	$	1,579,136	$	1,413,210
Related party loan-CEO loan		531,044		476,536
Related party loan – Line of credit		1,164,347		964,486
Accrued Interest		1,164,347		964,486

	Three months ended March 31, 2024		Three months ended March 31, 2023
Interest Expense
Related party loan-J&N	$	165,926	$	147,251
Related party loan-CEO loan		54,507		49,341
Related party loan – Line of Credit		199,861		144,956
Interest Expense		199,861		144,956

NATURE OF ORGANIZATION (Details Narrative) $ in Billions	3 Months Ended
NATURE OF ORGANIZATION (Details Narrative) $ in Billions	Mar. 31, 2024 USD ($) ft²
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other general expense \| $	$ 134
Area square foot \| ft²	51,000

SCHEDULE OF FAIR VALUE ASSETS MEASURED ON RECURRING BASIS (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Marketable Securities [Line Items]
Marketable securities	$ 9,504	$ 14,933
Fair Value, Inputs, Level 1 [Member]
Marketable Securities [Line Items]
Marketable securities		14,933
Fair Value, Inputs, Level 2 [Member]
Marketable Securities [Line Items]
Marketable securities
Fair Value, Inputs, Level 3 [Member]
Marketable Securities [Line Items]
Marketable securities
Marketable Securities [Member]
Marketable Securities [Line Items]
Marketable securities	9,504	14,933
Marketable Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Marketable Securities [Line Items]
Marketable securities		14,933
Marketable Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Marketable Securities [Line Items]
Marketable securities
Marketable Securities [Member] \| Fair Value, Inputs, Level 3 [Member]
Marketable Securities [Line Items]
Marketable securities

SCHEDULE OF MARKETABLE SECURITIES (Details) - USD ($)	3 Months Ended
SCHEDULE OF MARKETABLE SECURITIES (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Accounting Policies [Abstract]
Balance at beginning of year	$ 14,933
Realized loss on marketable securities, net	376
Unrealized loss on marketable securities, net	5,053	$ (182,255)
Balance at end of period	$ 9,504

SCHEDULE OF INTANGIBLE ASSETS AND GOODWILL (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	Oct. 31, 2017
Restructuring Cost and Reserve [Line Items]
Goodwill from N7 Acquisition	$ 3,014,450	$ 3,014,450
Total	$ 3,014,450	3,014,450
Phoenix Life Sciences, Inc. [Member]
Restructuring Cost and Reserve [Line Items]
Goodwill from Acquisition, Estimated Life	Tested Yearly for Impairment
Goodwill from N7 Acquisition	$ 2,188,810	2,188,810	$ 2,189,000
N7 Acquistion [Member]
Restructuring Cost and Reserve [Line Items]
Goodwill from Acquisition, Estimated Life	Tested Yearly for Impairment
Goodwill from N7 Acquisition	$ 825,640	$ 825,640	$ 825,000

SCHEDULE OF REVENUE FROM CONTRACT WITH CUSTOMER (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Balance, beginning of period	$ 349,705	$ 368,065
Payments received for unearned revenue	143,469	156,298
Revenue earned	92,219	174,658
Balance, end of period	$ 400,955	$ 349,705

SCHEDULE OF ANTI-DILUTIVE DILUTED LOSS PER SHARE (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	12,277,629	6,632,816
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	1,793,483	107,993
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	536,854	401,854
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	1,078,573	1,107,250
Series B-1 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	6,679	6,679
Series B-2 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	26,786	26,786
Series C Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	2,289,220	2,289,220
Series C-1 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	1,064,908	1,064,908
Series D Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	1,628,126	1,628,126
Series E Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	3,853,000

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Oct. 31, 2017
Property, Plant and Equipment [Line Items]
Accumulated deficit	$ 35,368,972		$ 33,922,898
Cash and liquid stock	117,000
Allowance for doubtful accounts	50,000
Allowance for doubtful expense	$ 0
Investment owned balance shares	79,200
Business acquisition, goodwill	$ 3,014,450		3,014,450
Customer advances payments	400,955		349,705
General and Administrative Expense [Member]
Property, Plant and Equipment [Line Items]
Shipping and handling costs	9,566	$ 29,667
Advertising expense	2,486	$ 8,769
Phoenix Life Sciences, Inc. [Member]
Property, Plant and Equipment [Line Items]
Business acquisition, goodwill	2,188,810		2,188,810	$ 2,189,000
N7 Acquistion [Member]
Property, Plant and Equipment [Line Items]
Business acquisition, goodwill	$ 825,640		$ 825,640	$ 825,000
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT USEFUL LIVES (Details)	Mar. 31, 2024
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	10 years
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Minimum [Member] \| Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Minimum [Member] \| Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Minimum [Member] \| Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	10 years
Maximum [Member] \| Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Maximum [Member] \| Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Maximum [Member] \| Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	10 years

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Total	$ 13,688,915	$ 13,683,915
Less accumulated depreciation	(7,619,345)	(7,235,847)
Total property and equipment, net	6,069,570	6,448,068
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	3,776,320	3,776,320
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total	166,830	161,830
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	7,846,788	7,846,788
Land [Member]
Property, Plant and Equipment [Line Items]
Total	92,222	92,222
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total	$ 1,806,755	$ 1,806,755

PROPERTY, EQUIPMENT, NET OF ACCUMULATED DEPRECIATION (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation expenses	$ 383,498	$ 422,554

SCHEDULE OF INVENTORY (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw Materials	$ 892,377	$ 850,362
Semi-Finished	1,785,949	1,870,978
Finished Goods	1,358,063	1,262,674
Packaging	26,438	29,511
Total	$ 4,062,827	$ 4,013,525

SCHEDULE OF RIGHT OF USE ASSET AND LIABILITY (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Operating Lease Right-of-use Assets And Operating Lease Liabilities Related Party
Right-of-use assets	$ 3,685,567	$ 3,864,591
Present value of operating lease liabilities	3,793,321	3,972,696
Less: Long-term portion of operating lease liability	(3,070,391)	(3,254,021)
Short-term portion of operating lease liability	722,930	718,675
Unpaid balances	2,300,802	2,185,758
Total short-term lease liability obligations	$ 3,023,732	$ 2,904,433
Weighted-average remaining lease term (Ends December 31, 2030)	5 years 9 months 3 days	5 years 11 months 15 days
Weighted-average discount rate		3.00%

SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITIES (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Operating Lease Right-of-use Assets And Operating Lease Liabilities Related Party
2024	$ 621,570
2025	830,307
2026	764,830
2027	474,122
Thereafter	1,451,002
Total undiscounted operating lease payments	4,141,831
Less: Imputed interest	(348,510)
Present value of operating lease liabilities	$ 3,793,321	$ 3,972,696

OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES – RELATED PARTY (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Lease expiring	Dec. 31, 2030
Present value of operating lease liabilities	$ 3,793,321		$ 3,972,696
Lease term	3 years
Operating lease, cost	$ 437,752	$ 114,693
Accounting Standards Update 2016-02 [Member]
Present value of operating lease liabilities	$ 4,595,509

SCHEDULE OF NOTES PAYABLE RELATED PARTY (Details) - Related Party [Member] - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Short-Term Debt [Line Items]
Total related party notes	$ 11,772,259	$ 11,397,617
J&N Note [Member]
Short-Term Debt [Line Items]
Total related party notes	4,062,713	4,062,713
CEO Note [Member]
Short-Term Debt [Line Items]
Total related party notes	$ 7,709,546	$ 7,334,904

SCHEDULE OF NOTES PAYABLE (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Total	$ 3,572,864	$ 3,572,864
Fixed Asset Loan [Member]
Defined Benefit Plan Disclosure [Line Items]
Total	3,059,474	3,059,474
JN Building Loan [Member]
Defined Benefit Plan Disclosure [Line Items]
Total	$ 513,390	$ 513,390	$ 513,390

NOTES PAYABLE (Details Narrative) - USD ($)	May 28, 2020	Mar. 31, 2024	Dec. 31, 2023	Jul. 01, 2022	Jun. 30, 2021	Dec. 31, 2020
Short-Term Debt [Line Items]
Other long-term liabilities, related party		$ 3,572,864	$ 3,572,864
Related Party [Member]
Short-Term Debt [Line Items]
Quintel Note		11,772,259	11,397,617
Fixed Asset Loan [Member]
Short-Term Debt [Line Items]
Other long-term liabilities, related party		3,059,474	3,059,474
JN Building Loan [Member]
Short-Term Debt [Line Items]
Other long-term liabilities, related party		513,390	513,390			$ 513,390
J&N Note [Member] \| Related Party [Member]
Short-Term Debt [Line Items]
Quintel Note		4,062,713	$ 4,062,713
Chief Executive Officer [Member] \| J&N Note [Member]
Short-Term Debt [Line Items]
Principal amount		$ 4,062,000.000
Debt instrument interest rate		12.00%
Chief Executive Officer [Member] \| J&N Note [Member] \| Related Party [Member]
Short-Term Debt [Line Items]
Quintel Note		$ 1,932,358
Chief Executive Officer [Member] \| Buttorff Note [Member]
Short-Term Debt [Line Items]
Debt instrument interest rate					10.00%
Percentage of promissory					10.00%
Quintel Note					$ 1,685,685
Additional line of credit note				$ 8,000,000	$ 1,000,000
Notes Payable [Member] \| US Small Business Administration [Member]
Short-Term Debt [Line Items]
Disaster loan amount	$ 99,100	99,100
Interest rate	3.75%
accured interest, payable		$ 2,047

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - USD ($)	3 Months Ended	12 Months Ended
SCHEDULE OF STOCK OPTION ACTIVITY (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Equity [Abstract]
Options outstanding, beginning	551,854
Weighted average exercise price per share outstanding, beginning	$ 1.84
Weighted average remaining contractual life outstanding, ending	2 years 10 months 28 days	3 years 2 months 4 days
Aggregate intrinsic value outstanding, warrants outstanding Beginning
Options granted
Weighted average exercise price per share, options granted
Options exercised
Weighted average exercise price per share, options exercised
Options canceled/expired	15,000
Weighted average exercise price per share, options canceled/expired
Options outstanding, ending	536,854	551,854
eighted average exercise price per share outstanding, ending	$ 1.88	$ 1.84
Aggregate intrinsic value outstanding, warrants outstanding Ending
Options vested and exercisable	196,491
Weighted Average exercise price per share outstanding, vested and exercisable	$ 1.88
Weighted average remaining contractual life outstanding, vested and exercisable	2 years 10 months 28 days
Aggregate intrinsic value outstanding, warrants outstanding vested and exercisable

SCHEDULE OF WARRANTS OUTSTANDING (Details) - USD ($)	3 Months Ended	12 Months Ended
SCHEDULE OF WARRANTS OUTSTANDING (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Equity [Abstract]
Number of Shares, warrants outstanding Beginning	1,104,243
Weighted average exercise price per share, warrants outstanding Beginning	$ 1.70
Weighted average remaining contractual life warrants outstanding	2 years 11 months 1 day	3 years 1 month 28 days
Aggregate intrinsic value outstanding, warrants outstanding Beginning
Number of Shares, granted
Weighted average exercise price per share, options granted
Number of Shares, exercised
Weighted average exercise price per share, options exercised
Number of Shares, canceled / expired	25,670
Weighted average exercise price per share, options canceled/expired	$ 5.60
Number of Shares, warrants outstanding Ending	1,078,573	1,104,243
Weighted average exercise price per share, warrants outstanding Ending	$ 1.70	$ 1.70
Aggregate intrinsic value outstanding, warrants outstanding Ending
Number of Shares, vested and exercisable	1,078,573
Weighted Average exercise price per share, warrants outstanding vested and exercisable	$ 1.70
Weighted average remaining contractual life warrants outstanding vested and exercisable	2 years 11 months 1 day
Aggregate intrinsic value outstanding, warrants outstanding vested and exercisable

SCHEDULE OF RESTRICTED STOCK (Details)	Mar. 31, 2024 shares
Equity [Abstract]
Restricted stock, ending balance	107,993
Restricted stock, ending balance	107,993

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)			3 Months Ended
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	Sep. 30, 2023	Jun. 30, 2021	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, authorized			650,000,000		650,000,000
Common stock, par value per share			$ 0.0001		$ 0.0001
Preferred stock, shares authorized			50,000,000
Preferred stock, par value per share			$ 0.0001
Series E Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized			3,853,000		3,853,000
Preferred stock, par value per share			$ 0.0001		$ 0.0001
Series E Preferred Stock [Member] \| N7 Enterprises, Inc [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Convertible preferred stock, shares issued upon conversion	785
Series E Preferred Stock [Member] \| N7 Enterprises, Inc [Member] \| Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, convertible, shares issuable	385
Employees and Directors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Debt instrument, unamortized discount			$ 0
2021 Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
New issuance of shares		4,049,409
Number of years shares available for grant		10 years
Option vested		196,491
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares convertible into common stock			666,000	540,000
Common Stock [Member] \| N7 Enterprises, Inc [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares convertible into common stock	10,000

COMMITMENTS AND CONTINGENCIES (Details Narrative) - Customer Concentration Risk [Member]	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue Benchmark [Member] \| One Customer [Member]
Loss Contingencies [Line Items]
Concentration Risk, Percentage	46.00%	31.00%
Revenue Benchmark [Member] \| Two Customer [Member]
Loss Contingencies [Line Items]
Concentration Risk, Percentage	13.00%	13.00%
Accounts Receivable [Member] \| Two Customer [Member]
Loss Contingencies [Line Items]
Concentration Risk, Percentage	54.00%
Accounts Receivable [Member] \| Customer Receivable [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Concentration Risk, Percentage	22.00%
Accounts Receivable [Member] \| Customer Receivable [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Concentration Risk, Percentage	54.00%
Accounts Receivable [Member] \| Other Customer One [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Concentration Risk, Percentage	31.00%

SCHEDULE OF RELATED PARTY TRANSACTIONS LOANS (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Related Party Transaction [Line Items]
Interest Expense	$ 429,672	$ 380,157
Related Party Loan J&N Real Estate [Member]
Related Party Transaction [Line Items]
Accrued Interest	1,579,136		$ 1,413,210
Interest Expense	165,926	147,251
Related Party Loan CEO Loan [Member]
Related Party Transaction [Line Items]
Accrued Interest	531,044		476,536
Interest Expense	54,507	49,341
Related Party Loan Line Of Credit [Member]
Related Party Transaction [Line Items]
Accrued Interest	1,164,347		$ 964,486
Interest Expense	$ 199,861	$ 144,956